vigabatrin has been researched along with Aura in 451 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients." | 9.12 | Vigabatrin - new data on indications and safety in paediatric epilepsy. ( Golec, W; Jóźwiak, S; Jurkiewicz, E; Sołowiej, E; Strzelecka, J, 2021) |
| "Reduced cerebral blood flow and decreased glucose metabolism have been identified in epilepsy patients receiving vigabatrin." | 9.10 | Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. ( Embleton, SJ; Gupta, AK; Hosking, SL; Roff Hilton, EJ, 2003) |
| "The aim of the present prospective study was to evaluate changes in plasma GABA concentration in relation to clinical response during vigabatrin treatment of epilepsy." | 9.09 | Changes in plasma GABA concentration during vigabatrin treatment of epilepsy: a prospective study. ( Alving, J; Erdal, J; Gram, L; Löscher, W, 1999) |
| "Vigabatrin (gamma-vinyl gamma aminobutyric acid), a recently developed antiepileptic drug, has been extensively evaluated in the treatment of drug-resistant epilepsy." | 9.09 | Aminoaciduria resulting from vigabatrin administration in children with epilepsy. ( Ben-Zeev, B; Lahat, E; Sela, BA; Zlotnik, J, 1999) |
| "Both examined antiepileptic drugs, vigabatrin and carbamazepine, cause acquired color vision defects." | 9.09 | Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. ( Kälviäinen, R; Mäntyjärvi, M; Nousiainen, I, 2000) |
| "To evaluate the efficacy, safety, and cognitive effects of initial vigabatrin monotherapy compared with initial carbamazepine monotherapy in patients with newly diagnosed epilepsy." | 9.08 | Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. ( Aikiä, M; Kälviäinen, R; Mervaala, E; Riekkinen, PJ; Saukkonen, AM, 1995) |
| "Patients with newly diagnosed localization-related epilepsy who participated in a VGB-carbamazepine (CBZ) monotherapy trial were included." | 9.08 | A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements. ( Connelly, A; Duncan, JS; Van Paesschen, W, 1998) |
| "The short- and long-term clinical efficacy of add-on vigabatrin treatment was evaluated in a group of 36 patients with intellectual disability and drug-refractory epilepsy." | 9.08 | Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. ( Ylinen, A, 1998) |
| "We evaluated the psychological effects of the antiepilepsy drug vigabatrin in a randomized multicenter double-blind placebo-controlled parallel group study that compared 3 grams oral vigabatrin with placebo as daily add-on therapy in patients with focal epilepsy whose complex partial seizures were difficult to control." | 9.07 | Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. ( Arnett, JL; Dodrill, CB; Sommerville, KW; Sussman, NM, 1993) |
| "Twenty-four patients with refractory epilepsy on one or more antiepileptic drugs were given additional vigabatrin (1 g twice daily for six weeks, followed by 1." | 9.07 | Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. ( Blacklaw, J; Brodie, MJ; Gillham, RA; McKee, PJ, 1993) |
| "The effects of adding vigabatrin (GVG) to the antiepileptic regimens of 16 children with refractory epilepsy have been studied." | 9.07 | Coadministration of vigabatrin and valproate in children with refractory epilepsy. ( Armijo, JA; Arteaga, R; Herranz, JL; Valdizán, EM, 1992) |
| "Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period." | 9.07 | Vigabatrin in childhood epilepsy. ( Beaumont, D; Chiron, C; Cusmai, R; Dulac, O; Luna, D; Mondragon, S; Pajot, N, 1991) |
| "At present, 34 patients aged 15 to 63 years with newly diagnosed epilepsy have been randomly assigned to vigabatrin (n = 17) or carbamazepine (n = 17)." | 9.07 | Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy: an interim report. ( Aikiä, M; Kälviäinen, R; Mumford, J; Partanen, J; Riekkinen, PJ; Saksa, M; Sivenius, J, 1991) |
| "The effects of the addition of Vigabatrin, a new anti-epileptic drug, to the therapy of 128 patients with severe medically refractory epilepsy is reported." | 9.06 | Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. ( Hart, YM; Sander, JW; Shorvon, SD; Trevisol-Bittencourt, PC, 1990) |
| " A meta-analysis has been performed on nine placebo controlled trials of vigabatrin (GVG) administered as add-on therapy to patients suffering from drug resistant epilepsy." | 9.06 | Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. ( Dam, M; Mumford, JP, 1989) |
| " The long term safety and efficacy of vigabatrin has been studied in 254 patients with refractory epilepsy (82% with partial seizures) in 23 different clinics in eight European countries." | 9.06 | Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. ( Beaumont, D; Remy, C, 1989) |
| "The efficacy and safety of vigabatrin (VGB) as an add-on therapy for refractory epilepsy have been well established." | 8.91 | Vigabatrin versus carbamazepine monotherapy for epilepsy. ( Gan, L; Luo, H; Luo, M; Wang, J; Xiao, Y, 2015) |
| "The efficacy and safety of vigabatrin (VGB) as an add-on therapy for refractory epilepsy has been well established." | 8.88 | Vigabatrin versus carbamazepine monotherapy for epilepsy. ( Gan, L; Luo, H; Luo, M; Wang, J; Xiao, Y, 2012) |
| "Vigabatrin (Sabril, Hoechst Marion Roussel) is an antiepilepsy drug (AED) presently marketed in 64 countries for the treatment of partial and secondarily generalized seizures." | 8.80 | The potential for vigabatrin-induced intramyelinic edema in humans. ( Brigell, MG; Cohen, JA; Fisher, RS; Peyster, RG; Sze, G, 2000) |
| "Vigabatrin has been studied in adult drug-resistant epilepsy since 1982 in single-blind and double-blind studies followed by long-term, open evaluations." | 8.78 | Vigabatrin in refractory epilepsy in adults and its application in children. ( Dam, M, 1991) |
| "To report a prospectively planned analysis of two randomised controlled trials with embedded comparisons of prednisolone versus tetracosactide depot for the treatment of infantile epileptic spasms syndrome (IESS)." | 8.31 | Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. ( Alber, FD; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2023) |
| "Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known." | 7.88 | Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. ( Peters, JM; Sahin, M; van der Poest Clement, EA, 2018) |
| "To evaluate the efficacy and safety of vigabatrin in pediatric epilepsy." | 7.85 | Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. ( Coughlin, F; Jackson, MC; Jafarpour, S; Kapur, K; Klehm, J; Loddenkemper, T; Thome-Souza, S, 2017) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 7.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| "To characterize the type of interactions between vigabatrin (VGB) and tiagabine (TGB) -- two newer antiepileptic drugs influencing GABA-ergic neurotransmitter system, the isobolographic analysis was used in two experimental models of epilepsy: the maximal electroshock seizure threshold (MEST) test and pentylenetetrazole (PTZ)-induced seizures in mice." | 7.74 | Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ, 2007) |
| "Interim analysis of three groups with refractory partial epilepsy, stratified by age (8-12 years; >12 years) and exposure to vigabatrin (VGB)." | 7.74 | Vigabatrin and epilepsy: lessons learned. ( Ahn, HS; Baulac, M; Bursztyn, J; Chiron, C; Gandolfo, E; Perucca, E; Safran, AB; Schiefer, U; Wild, JM, 2007) |
| "Vigabatrin was a major drug in the treatment of epilepsy until the discovery that it was associated with an irreversible constriction of the visual field." | 7.74 | Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. ( Craft, CM; Duboc, A; Dubus, E; Gong, J; Jammoul, F; Picaud, S; Sahel, JA; Simonutti, M; Wang, QP; Ye, W, 2008) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 7.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "The aim of the study was to obtain pharmacokinetic data for carbamazepine (CBZ) and its fractions not bound with proteins in bitherapy with lamotrigine (LTG), topiramate (TPM), vigabatrin (VGB) or valproic acid (VPA) in children and adolescents treated for epilepsy." | 7.73 | Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents. ( Steinborn, B, 2005) |
| "Authors presented the data on the efficacy and tolerability of the new anticonvulsant drug topiramate (topamax) in the treatment of 110 children aged from 6 months to 16 years with pharmacoresistant types of epilepsy including 42 patients with tuberous sclerosis." | 7.73 | [The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children]. ( Belousova, ED; Dorofeeva, MIu; Ermakov, AIu, 2005) |
| "Retrospective review of 583 patients prescribed vigabatrin at any time between 1989 and 2001 from a regional and satellite epilepsy clinic." | 7.71 | The legacy of vigabatrin in a regional epilepsy clinic. ( Chadwick, DW; Leach, JP; Nicolson, A; Smith, DF, 2002) |
| "Visual field constriction (VFC) occurs in approximately 40 % of epilepsy patients under treatment with vigabatrin (VGB)." | 7.71 | Is visual field constriction in epilepsy patients treated with vigabatrin reversible? ( Jokiel, B; Pfeiffer, S; Rüther, K; Schmidt, T; Schmitz, B; Tiel-Wilck, K, 2002) |
| "Using [11C]flumazenil (FMZ)-positron emission tomography (PET) imaging, 15 children (aged 1-8 years) with medically intractable epilepsy were studied." | 7.71 | Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy. ( Chugani, DC; Chugani, HT; Janisse, J; Juhász, C; Muzik, O; Shen, C, 2001) |
| "New antiepileptic drugs designed for enhancing GABAergic inhibition, such as vigabatrin (VGB) may be effective in Angelman syndrome (AS), because associated convulsions could be related to a reduced GABA-receptor density or receptor abnormality." | 7.70 | Adverse effects of vigabatrin in Angelman syndrome. ( Boltshauser, E; Kuenzle, C; Schmitt, B; Steinlin, M; Wohlrab, G, 1998) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 7.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "To determine the efficacy of a new anti-epileptic medication vigabatrin in adults and children with drug-resistant epilepsy." | 7.69 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "In an retrospective uncontrolled long-term study in 30 children with intractable epilepsy, it was found that treatment with vigabatrin resulted in a seizure reduction of more than 50% at 1-year follow-up in 40% of the children." | 7.69 | Vigabatrin in childhood epilepsy: a 5-year follow-up study. ( Alving, J; Gram, L; Høgenhaven, H; Uldall, P, 1995) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 7.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described." | 7.69 | Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). ( Bird, JM; Lambert, MV, 1997) |
| "A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales." | 7.69 | A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. ( Gordon, GS; Schapel, GJ; Wallace, SJ, 1997) |
| "The long-term clinical, neurophysiologic, and psychological effects of add-on vigabatrin treatment were evaluated in a group of 36 mentally handicapped patients with drug-refractory epilepsy." | 7.68 | Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients. A 5-year follow-up study. ( Luukkainen, R; Matilainen, R; Mervaala, E; Pitkänen, A; Riekkinen, PJ; Ruutiainen, T; Seppänen, R; Ylinen, A, 1993) |
| "Twenty-five patients with epilepsy (mostly with partial seizures) who had responded favourably to a short-term trial of add-on vigabatrin entered maintenance treatment." | 7.68 | Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. ( Galimberti, CA; Iudice, A; Manni, R; Morini, R; Mumford, JP; Perucca, E; Tartara, A, 1992) |
| " This study presents the results of the preliminary screening of vigabatrin as add-on therapy in an open, non-controlled multicentre study in children with refractory epilepsy." | 7.67 | Vigabatrin in the treatment of epilepsy in children. ( Aicardi, J; Arzimanoglou, A; Beaumont, D; Livingston, JH, 1989) |
| " The anticonvulsant potency of vigabatrin (gamma-vinyl GABA, GVG) was studied in an open trial in a group of 21 mentally handicapped patients with drug-resistant epilepsy." | 7.67 | Vigabatrin in epilepsy in mentally retarded patients. ( Matilainen, R; Mervaala, E; Pitkänen, A; Riekkinen, P; Ruutiainen, T, 1989) |
| "In studies spanning more than 5 years, more than 1,100 patients with epilepsy have been treated with vigabatrin (gamma vinyl GABA, GVG)." | 7.67 | Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy. ( Dam, M, 1989) |
| "We studied the antiepileptic potency of vigabatrin (gamma-vinyl GABA, GVG) as an open trial in a group of 36 mentally handicapped patients with drug-resistant epilepsy (30 had seizures of partial onset and 6 had primary generalized [PG] tonic-clonic convulsions)." | 7.67 | Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study. ( Matilainen, R; Mervaala, E; Pitkänen, A; Riekkinen, P; Ruutiainen, T; Sarlund, H, 1988) |
| "Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity." | 6.71 | The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. ( Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2005) |
| "Vigabatrin (VGB) is a new antiepileptic drug that increases the human brain gamma-aminobutyric acid (GABA) level by irreversibly inhibiting GABA transaminase." | 6.70 | Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. ( Boesiger, P; Duc, CO; Meier, D; Mueller, SG; Russ, W; Weber, B; Weber, OM; Wieser, HG, 2001) |
| " We evaluated the cognitive and quality-of-life (QOL) effects of VGB in a double-blinded, add-on, placebo-controlled, parallel group dose-response study of patients with focal epilepsy whose complex partial seizures (CPS) were difficult to control." | 6.68 | Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. ( Arnett, JL; Dodrill, CB; Sommerville, KW; Sussman, NM, 1995) |
| "Vigabatrin was most effective in cryptogenic and symptomatic partial seizures (39% and 43%, respectively), and in infantile spasms (25%)." | 6.68 | Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. ( Coppola, G; Pascotto, A; Terraciano, AM, 1997) |
| "To date, 27 children with partial epilepsy, two with generalized epilepsy, two with Lennox-Gastaut syndrome, and one with nonclassifiable epilepsy have been enrolled in the trial." | 6.67 | Vigabatrin in pediatric epilepsy--an open study. ( Alving, J; Beck, S; Gram, L; Uldall, P, 1991) |
| "Twenty children aged 2 months to 18 years were included in a dose-response study of vigabatrin as add-on therapy to preexisting antiepileptic drugs (up to two per patient)." | 6.67 | Dose-response study of vigabatrin in children with refractory epilepsy. ( Armijo, JA; Arteaga, R; Beaumont, D; Farr, IN; Herranz, JL; Valdizan, E, 1991) |
| "Vigabatrin is a selective, irreversible suicide inhibitor of GABA transaminase and thus increases brain and CSF GABA." | 6.67 | Vigabatrin: rational treatment for chronic epilepsy. ( Farr, IN; Heller, AJ; Reynolds, EH; Ring, HA, 1990) |
| "1." | 6.66 | A multicentre study of vigabatrin for drug-resistant epilepsy. ( Ben-Menachem, E; Browne, TR; Mattson, RH; Miketta, RM; Penry, JK; Sherry, KM; Smith, DB; Szabo, GK; Treiman, DM; Wilder, BJ, 1989) |
| "Vigabatrin was found to have a frequent and irreversible retinal toxicity, which required an alternative visual testing to be detected in young children." | 6.53 | Stiripentol and vigabatrin current roles in the treatment of epilepsy. ( Chiron, C, 2016) |
| "Vigabatrin (VGB) is a new antiepileptic drug, that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase." | 6.42 | [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy]. ( Bakunowicz-Łazarczyk, A; Mrugacz, M, 2003) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 6.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "The repertoire of available and developmental therapies for epilepsy is rapidly expanding, and now includes disease-modifying vigabatrin in TSC and agents with extraordinary efficacy, fenfluramine and cenobamate." | 5.41 | Recent advances in pharmacotherapy for epilepsy. ( Klein, P; Pong, AW; Xu, KJ, 2023) |
| "Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy." | 5.41 | Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. ( Aronica, E; Benova, B; Borkowska, J; Curatolo, P; de Ridder, J; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Hulshof, H; Jansen, AC; Jansen, F; Jóźwiak, S; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Moavero, R; Nabbout, R; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Weschke, B; Wojdan, K, 2021) |
| "Early EEG findings help to identify TSC infants at risk of severe epilepsy and neurodevelopmental delay and those who may benefit from preventive treatment with vigabatrin." | 5.41 | Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes. ( Aronica, E; Benova, B; Curatolo, P; De Ridder, J; Domanska-Pakieła, D; Ferrier, CH; Feucht, M; Hertzberg, C; Jansen, AC; Jansen, FE; Jóźwiak, S; Kaczorowska-Frontczak, M; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Lemmens, K; Moavero, R; Nabbout, R; Riney, K; Samueli, S; Verhelle, B; Vervisch, J; Weschke, B; Wojdan, K, 2021) |
| "Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase." | 5.40 | Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ( Karim, A; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2014) |
| "Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation." | 5.38 | Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. ( Backofen-Wehrhahn, B; Bankstahl, M; Bröer, S; Gernert, M; Gey, L; Löscher, W, 2012) |
| "1." | 5.31 | [Vigabatrin in the treatment of intractable focal epilepsy in children and adolescents. Two-year study]. ( Grotowska, M; Kozik, A; Ujma-Czapska, B, 2000) |
| "Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms." | 5.31 | Visual impairment in children with epilepsy treated with vigabatrin. ( Banin, E; Gross-Tsur, V; Lahat, E; Shahar, E; Shalev, RS, 2000) |
| "Vigabatrin dose was 25-114 mg/kg/day (mean 55." | 5.31 | Vigabatrin associated retinal dysfunction in children with epilepsy. ( Al Riyami, K; Bulusu, S; Chacko, A; Ganesh, A; Koul, R, 2001) |
| "We performed a prospective, nonrandomized clinical trial with 14 infants diagnosed with tuberous sclerosis complex in whom serial electroencephalographic recordings were performed and preventive treatment with vigabatrin initiated when active epileptic discharges were detected." | 5.30 | Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial. ( Borkowska, J; Chmielewski, D; Domańska-Pakieła, D; Głowacka, J; Jozwiak, S; Kaczorowska-Frontczak, M; Kotulska, K; Sadowski, K; Sijko, K; Słowińska, M; Łojszczyk, B, 2019) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Vigabatrin was well tolerated, we did not experience any serous adverse reactions." | 5.30 | [Vigabatrin in childhood epilepsy--personal experience]. ( Buljina, A; Catibusić, F; Gavranović, M; Uzicanin, S; Zubcević, S, 1999) |
| "Vigabatrin is a new antiepileptic drug that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase." | 5.28 | Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. ( Butler, WH; Cannon, DJ; Lewis, PJ; Mumford, JP, 1991) |
| "Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients." | 5.12 | Vigabatrin - new data on indications and safety in paediatric epilepsy. ( Golec, W; Jóźwiak, S; Jurkiewicz, E; Sołowiej, E; Strzelecka, J, 2021) |
| "Reduced cerebral blood flow and decreased glucose metabolism have been identified in epilepsy patients receiving vigabatrin." | 5.10 | Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. ( Embleton, SJ; Gupta, AK; Hosking, SL; Roff Hilton, EJ, 2003) |
| "Unlike vigabatrin, tiagabine treatment is associated with normal electroretinography and visual fields and ophthalmological function similar to epilepsy control patients." | 5.10 | A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. ( Johnson, MA; Krauss, GL; Miller, NR; Sheth, S, 2003) |
| "The aim of the study was to assess the prevalence of visual field constriction in a consecutive, unselected series of patients in the Copenhagen area treated with vigabatrin for severe epilepsy, and further to assess appropriate screening techniques for detecting such visual field defects." | 5.10 | [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods]. ( Fledelius, HC; Riise, P; Rogvi-Hansen, Bà, 2003) |
| "The objective of this study was to compare the efficacy of corticotropin (ACTH) versus vigabatrin in treating infantile spasms and to determine which medication has a more favorable long-term outcome in terms of cognitive function, evolution of epilepsy, and incidence of autism." | 5.10 | Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. ( Askalan, R; Boyd, J; Brian, J; Bryson, S; Mackay, M; McDermott, C; Otsubo, H; Roberts, W; Snead, C; Weiss, S, 2003) |
| "To derive a visual-evoked potential (VEP) technique for identifying visual field defects in children with epilepsy treated with vigabatrin and unable to perform perimetry." | 5.10 | Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. ( Bohn, RL; Conway, M; Harding, GF; Spencer, EL; Wild, JM, 2002) |
| "Ten patients with refractory partial epilepsy, previous mental retardation and psychosis or other significant psychiatric morbidity treated with vigabatrin were submitted periodically to specific tests (to quantify any possible change in behavioural parameters) and also to EEG recordings." | 5.09 | Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. ( Baldi, PL; De Agostini, G; Ferrari Ginevra, O; Lanzi, G; Muzio, C; Termine, C; Veggiotti, P, 1999) |
| "The aim of the present prospective study was to evaluate changes in plasma GABA concentration in relation to clinical response during vigabatrin treatment of epilepsy." | 5.09 | Changes in plasma GABA concentration during vigabatrin treatment of epilepsy: a prospective study. ( Alving, J; Erdal, J; Gram, L; Löscher, W, 1999) |
| "Vigabatrin (gamma-vinyl gamma aminobutyric acid), a recently developed antiepileptic drug, has been extensively evaluated in the treatment of drug-resistant epilepsy." | 5.09 | Aminoaciduria resulting from vigabatrin administration in children with epilepsy. ( Ben-Zeev, B; Lahat, E; Sela, BA; Zlotnik, J, 1999) |
| "Both examined antiepileptic drugs, vigabatrin and carbamazepine, cause acquired color vision defects." | 5.09 | Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. ( Kälviäinen, R; Mäntyjärvi, M; Nousiainen, I, 2000) |
| "To evaluate the efficacy, safety, and cognitive effects of initial vigabatrin monotherapy compared with initial carbamazepine monotherapy in patients with newly diagnosed epilepsy." | 5.08 | Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. ( Aikiä, M; Kälviäinen, R; Mervaala, E; Riekkinen, PJ; Saukkonen, AM, 1995) |
| "Patients with newly diagnosed localization-related epilepsy who participated in a VGB-carbamazepine (CBZ) monotherapy trial were included." | 5.08 | A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements. ( Connelly, A; Duncan, JS; Van Paesschen, W, 1998) |
| "The short- and long-term clinical efficacy of add-on vigabatrin treatment was evaluated in a group of 36 patients with intellectual disability and drug-refractory epilepsy." | 5.08 | Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. ( Ylinen, A, 1998) |
| "We evaluated the psychological effects of the antiepilepsy drug vigabatrin in a randomized multicenter double-blind placebo-controlled parallel group study that compared 3 grams oral vigabatrin with placebo as daily add-on therapy in patients with focal epilepsy whose complex partial seizures were difficult to control." | 5.07 | Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. ( Arnett, JL; Dodrill, CB; Sommerville, KW; Sussman, NM, 1993) |
| "Twenty-four patients with refractory epilepsy on one or more antiepileptic drugs were given additional vigabatrin (1 g twice daily for six weeks, followed by 1." | 5.07 | Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. ( Blacklaw, J; Brodie, MJ; Gillham, RA; McKee, PJ, 1993) |
| "The effects of adding vigabatrin (GVG) to the antiepileptic regimens of 16 children with refractory epilepsy have been studied." | 5.07 | Coadministration of vigabatrin and valproate in children with refractory epilepsy. ( Armijo, JA; Arteaga, R; Herranz, JL; Valdizán, EM, 1992) |
| "Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period." | 5.07 | Vigabatrin in childhood epilepsy. ( Beaumont, D; Chiron, C; Cusmai, R; Dulac, O; Luna, D; Mondragon, S; Pajot, N, 1991) |
| "At present, 34 patients aged 15 to 63 years with newly diagnosed epilepsy have been randomly assigned to vigabatrin (n = 17) or carbamazepine (n = 17)." | 5.07 | Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy: an interim report. ( Aikiä, M; Kälviäinen, R; Mumford, J; Partanen, J; Riekkinen, PJ; Saksa, M; Sivenius, J, 1991) |
| "The effects of the addition of Vigabatrin, a new anti-epileptic drug, to the therapy of 128 patients with severe medically refractory epilepsy is reported." | 5.06 | Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. ( Hart, YM; Sander, JW; Shorvon, SD; Trevisol-Bittencourt, PC, 1990) |
| " A meta-analysis has been performed on nine placebo controlled trials of vigabatrin (GVG) administered as add-on therapy to patients suffering from drug resistant epilepsy." | 5.06 | Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. ( Dam, M; Mumford, JP, 1989) |
| " The long term safety and efficacy of vigabatrin has been studied in 254 patients with refractory epilepsy (82% with partial seizures) in 23 different clinics in eight European countries." | 5.06 | Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. ( Beaumont, D; Remy, C, 1989) |
| " Somatosensory (SEP) brainstem auditory (BAEP) and visual (VEP) evoked potentials were determined before and after add-on administration of vigabatrin (GVG) in patients with epilepsy." | 5.06 | Effects of vigabatrin on evoked potentials in epileptic patients. ( Callieco, R; Cosi, V; Galimberti, CA; Manni, R; Mumford, J; Perucca, E; Tartara, A, 1989) |
| "Vigabatrin (VGB) is currently served as an effective adjunctive therapy for patients with partial epilepsy worldwide." | 4.95 | Reduction of retinal nerve fiber layer thickness in vigabatrin-exposed patients: A meta-analysis. ( He, Y; Hu, W; Hu, Y; Peng, Y; Zhao, Y; Zhou, Y, 2017) |
| "The efficacy and safety of vigabatrin (VGB) as an add-on therapy for refractory epilepsy have been well established." | 4.91 | Vigabatrin versus carbamazepine monotherapy for epilepsy. ( Gan, L; Luo, H; Luo, M; Wang, J; Xiao, Y, 2015) |
| "The efficacy and safety of vigabatrin (VGB) as an add-on therapy for refractory epilepsy has been well established." | 4.88 | Vigabatrin versus carbamazepine monotherapy for epilepsy. ( Gan, L; Luo, H; Luo, M; Wang, J; Xiao, Y, 2012) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)." | 4.87 | Epilepsy (partial). ( Maguire, M; Marson, AG; Ramaratnam, S, 2011) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)." | 4.86 | Epilepsy (partial). ( Maguire, M; Marson, AG; Ramaratnam, S, 2010) |
| " As the result of the detailed analysis of the literature the author recommends lamotrigine, carbamazepine and oxcarbazepine as first choice antiepileptic drug for epileptic patients suffering from depressive disorder, too." | 4.84 | [Effects of antiepileptic drugs on mood of people with epilepsy]. ( Rajna, P, 2007) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "Vigabatrin (Sabril, Hoechst Marion Roussel) is an antiepilepsy drug (AED) presently marketed in 64 countries for the treatment of partial and secondarily generalized seizures." | 4.80 | The potential for vigabatrin-induced intramyelinic edema in humans. ( Brigell, MG; Cohen, JA; Fisher, RS; Peyster, RG; Sze, G, 2000) |
| "Vigabatrin is undoubtedly one of the most exciting anti-epilepsy drugs in use today." | 4.79 | Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. ( Behar, K; Mattson, RH; Petroff, OA; Rothman, D, 1995) |
| "Vigabatrin is among the most promising of the new anti-epilepsy drugs, but two unrelated complications have been noted in patients receiving vigabatrin for chronic refractory epilepsy." | 4.79 | Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. ( Schmidt, D, 1995) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 4.79 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "A 7-year-old boy with intractable epilepsy developed acute psychosis 3 days after initiating a rapid vigabatrin dosage escalation." | 4.79 | Vigabatrin-associated reversible acute psychosis in a child. ( Beltrán Marqués, M; Cánovas Martínez, A; Delgado Cordón, F; Escrivá Aparisi, A; Ordovás Baines, JP, 1995) |
| "To evaluate the efficacy and tolerability of the newly developed antiepileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide in patients with refractory partial epilepsy." | 4.79 | New antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Kadir, ZA; Marson, AG, 1996) |
| "Gabapentin (GBP), lamotrigine (LTG), tiagabine (TGB), topiramate (TPM), vigabatrin (VGB), and zonisamide (ZNS) are all in use as "add-on" treatment for patients with refractory epilepsy." | 4.79 | The new antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Hutton, JL; Kadir, ZA; Marson, AG, 1997) |
| "More than 360 children with intractable epilepsy have been treated with vigabatrin in single-blind or open, add-on studies." | 4.78 | The role of vigabatrin in the management of infantile epileptic syndromes. ( Appleton, RE, 1993) |
| "Vigabatrin has been studied in adult drug-resistant epilepsy since 1982 in single-blind and double-blind studies followed by long-term, open evaluations." | 4.78 | Vigabatrin in refractory epilepsy in adults and its application in children. ( Dam, M, 1991) |
| "To report a prospectively planned analysis of two randomised controlled trials with embedded comparisons of prednisolone versus tetracosactide depot for the treatment of infantile epileptic spasms syndrome (IESS)." | 4.31 | Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. ( Alber, FD; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2023) |
| "We present a comprehensive multi-omic analysis of the EPISTOP prospective clinical trial of early intervention with vigabatrin for pre-symptomatic epilepsy treatment in Tuberous Sclerosis Complex (TSC), in which 93 infants with TSC were followed from birth to age 2 years, seeking biomarkers of epilepsy development." | 4.31 | Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years. ( Anink, JJ; Aronica, E; Asara, JM; Blazejczyk, M; Borkowska, J; Curatolo, P; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Huschner, F; Iyer, A; Jansen, AC; Jansen, FE; Janson, S; Janssen, B; Jaworski, J; Jozwiak, S; Klonowska, K; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Lasseter, K; Lehmann, K; Mijnsbergen, C; Mills, JD; Moavero, R; Mühlebner, A; Nabbout, R; Petrák, B; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Tempes, A; Urbanska, M; van Scheppingen, J; Weschke, B; Wojdan, K; Zamecnik, J, 2023) |
| " Prophylactic intervention with sirolimus and vigabatrin may reduce the incidence of epilepsy." | 4.12 | Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex. ( Ding, Y; Wang, J; Wang, X; Wang, Y; Yu, L; Zhou, S; Zhou, Y, 2022) |
| " OV329, a novel drug candidate for the treatment of epilepsy and addiction, has been shown in vitro to be substantially more potent as a GABA-AT inactivator than vigabatrin, an antiseizure drug approved as an add-on therapy for adult patients with refractory complex partial seizures and monotherapy for pediatric patients with infantile spasms." | 4.02 | OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats. ( Deking, LS; During, MJ; Feja, M; Gernert, M; Kaczmarek, E; Meller, S; Silverman, RB, 2021) |
| " We discuss the recent trials of vigabatrin to prevent onset and modify epilepsy outcome in children with tuberous sclerosis (Epistop and PreVeNT)." | 4.02 | Antiepileptogenesis and disease modification: Clinical and regulatory issues. ( Bebin, M; Dichter, MA; Engel, J; French, JA; Hartman, AL; Jóźwiak, S; Klein, P; McNamara, J; Twyman, R; Vespa, P, 2021) |
| " The staging of the loss could assist the risk:benefit analysis of vigabatrin for the treatment of epilepsy." | 3.91 | Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy. ( Knupp, C; Smith, PEM; Wild, JM, 2019) |
| "Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known." | 3.88 | Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. ( Peters, JM; Sahin, M; van der Poest Clement, EA, 2018) |
| "To evaluate the efficacy and safety of vigabatrin in pediatric epilepsy." | 3.85 | Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. ( Coughlin, F; Jackson, MC; Jafarpour, S; Kapur, K; Klehm, J; Loddenkemper, T; Thome-Souza, S, 2017) |
| "The aim of the study was to evaluate the relationship between the area of isopters obtained using semi-automated kinetic perimetry (SKP) and Vigabatrin dosage in epilepsy patients with pretreatment baseline examination during 2-years of the follow-up." | 3.80 | Relationship between the area of isopters and Vigabatrin dosage during two years of observation. ( Brzozowska, A; Jedrych, M; Juenemann, AG; Koss, MJ; Ksiazek, K; Ksiazek, P; Maciejewski, R; Nowomiejska, K; Rejdak, K; Rejdak, R; Schiefer, U; Zarnowski, T, 2014) |
| "From a group of 201 vigabatrin-exposed individuals with epilepsy, fourteen individuals were identified who were currently taking vigabatrin." | 3.79 | Evolution of visual field loss over ten years in individuals taking vigabatrin. ( Acheson, J; Clayton, LM; Newman, WD; Sander, JW; Sisodiya, SM; Stern, WM, 2013) |
| "Subjects were older than 18 years, 129 with vigabatrin-treated epilepsy (vigabatrin-exposed group) and 87 individuals with epilepsy never treated with vigabatrin (nonexposed group)." | 3.78 | Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals. ( Acheson, JF; Clayton, LM; de Haan, GJ; Devile, M; Punte, T; Sander, JW; Sisodiya, SM, 2012) |
| "Two hundred one vigabatrin-exposed subjects with epilepsy, divided into 2 groups, and 90 healthy controls participated." | 3.77 | Retinal nerve fiber layer thickness in vigabatrin-exposed patients. ( Acheson, J; Clayton, LM; de Haan, GJ; Dévilé, M; Kallis, C; Punte, T; Sander, JW; Sisodiya, SM, 2011) |
| " We retrospectively evaluated the long-term outcome of 44 infants presenting with seizures in the first 12 months who received vigabatrin, and were followed up for at least 3." | 3.77 | Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. ( Bombardieri, R; Curatolo, P; Cusmai, R; Moavero, R; Vigevano, F, 2011) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 3.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| "To evaluate white sphere kinetic perimetry (WSKP) as a test of the peripheral visual field in young children with a history of epilepsy and treatment with Vigabatrin (VGB)." | 3.75 | Visual fields in young children treated with vigabatrin. ( Agrawal, S; Fulton, AB; Hansen, RM; Mayer, DL, 2009) |
| "To characterize the type of interactions between vigabatrin (VGB) and tiagabine (TGB) -- two newer antiepileptic drugs influencing GABA-ergic neurotransmitter system, the isobolographic analysis was used in two experimental models of epilepsy: the maximal electroshock seizure threshold (MEST) test and pentylenetetrazole (PTZ)-induced seizures in mice." | 3.74 | Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ, 2007) |
| "Interim analysis of three groups with refractory partial epilepsy, stratified by age (8-12 years; >12 years) and exposure to vigabatrin (VGB)." | 3.74 | Vigabatrin and epilepsy: lessons learned. ( Ahn, HS; Baulac, M; Bursztyn, J; Chiron, C; Gandolfo, E; Perucca, E; Safran, AB; Schiefer, U; Wild, JM, 2007) |
| "Vigabatrin was a major drug in the treatment of epilepsy until the discovery that it was associated with an irreversible constriction of the visual field." | 3.74 | Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. ( Craft, CM; Duboc, A; Dubus, E; Gong, J; Jammoul, F; Picaud, S; Sahel, JA; Simonutti, M; Wang, QP; Ye, W, 2008) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 3.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "The aim of the study was to obtain pharmacokinetic data for carbamazepine (CBZ) and its fractions not bound with proteins in bitherapy with lamotrigine (LTG), topiramate (TPM), vigabatrin (VGB) or valproic acid (VPA) in children and adolescents treated for epilepsy." | 3.73 | Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents. ( Steinborn, B, 2005) |
| "Vigabatrin is a GABA mimetic antiepileptic agent that has been used for 10 years in cases of epilepsy that resist other treatments." | 3.73 | [Electrophysiological monitoring of epileptic patients treated with Vigabatrin]. ( Baulac, M; Nordmann, JP; Rigolet, MH, 2005) |
| "Authors presented the data on the efficacy and tolerability of the new anticonvulsant drug topiramate (topamax) in the treatment of 110 children aged from 6 months to 16 years with pharmacoresistant types of epilepsy including 42 patients with tuberous sclerosis." | 3.73 | [The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children]. ( Belousova, ED; Dorofeeva, MIu; Ermakov, AIu, 2005) |
| " The child was treated with vigabatrin at age 6 months after an abnormal electroencephalogram but before onset of seizures." | 3.73 | Autistic regression associated with seizure onset in an infant with tuberous sclerosis. ( Bolton, PF; Clarke, A; Humphrey, A; Neville, BG, 2006) |
| "To evaluate through a longitudinal study the effects on visual fields of long-term vigabatrin medication in patients with partial epilepsy and to discuss visual field screening strategies." | 3.72 | Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. ( Fledelius, HC, 2003) |
| "Six patients with epilepsy treated with vigabatrin as add-on therapy for at least 3 years were included in this observational case series." | 3.72 | Retinal function abnormalities in patients treated with vigabatrin. ( Banin, E; Chowers, I; Gross-Tsur, V; Neis, R; Obolensky, A; Shalev, RS, 2003) |
| "The utility of vigabatrin in the treatment of epilepsy is partially offset by its retinal toxicity." | 3.72 | Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. ( Frisén, L, 2004) |
| "We described course of disease of a 12 year old boy with epilepsy, treated with vigabatrin." | 3.72 | [Changes in visual field of a child treatment with vigabatrin for 2 years]. ( Bakunowicz-Łazarczyk, A; Mrugacz, M, 2003) |
| "Vigabatrin (VGB) has been widely used in patients affected by drug-resistant epilepsy and West syndrome." | 3.72 | Scotopic threshold response changes after vigabatrin therapy in a child without visual field defects: a new electroretinographic marker of early damage? ( Manfredi, M; Parisi, P; Piazza, G; Tommasini, P, 2004) |
| "Retrospective review of 583 patients prescribed vigabatrin at any time between 1989 and 2001 from a regional and satellite epilepsy clinic." | 3.71 | The legacy of vigabatrin in a regional epilepsy clinic. ( Chadwick, DW; Leach, JP; Nicolson, A; Smith, DF, 2002) |
| "Visual field constriction (VFC) occurs in approximately 40 % of epilepsy patients under treatment with vigabatrin (VGB)." | 3.71 | Is visual field constriction in epilepsy patients treated with vigabatrin reversible? ( Jokiel, B; Pfeiffer, S; Rüther, K; Schmidt, T; Schmitz, B; Tiel-Wilck, K, 2002) |
| "Vigabatrin, a gamma-amino butyric acid (GABA) transaminase inhibitor, is known to inhibit partial epilepsy in humans." | 3.71 | Effects of vigabatrin on epileptiform abnormal discharges in hippocampal CA3 neurons of spontaneously epileptic rats (SER). ( Hanaya, R; Kiura, Y; Kurisu, K; Sasa, M; Serikawa, T, 2002) |
| "This postmarketing surveillance study of lamotrigine (LTG) was performed to provide complementary data to large-scale Prescription-Event Monitoring study with a retrospective case records survey in five tertiary referral epilepsy centres in the United Kingdom." | 3.71 | Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. ( Mawer, GE; Sander, JW; Wong, IC, 2001) |
| "To describe the correlation between visual field loss and the duration, dosage, and total amount of vigabatrin (VGB) medication in a group of patients with epilepsy." | 3.71 | Visual field loss associated with vigabatrin: quantification and relation to dosage. ( Berendschot, TT; Edelbroek, PM; Engelsman, M; Hardus, P; Segers, JP; Stilma, JS; Verduin, WM, 2001) |
| "Vigabatrin (VGB) treatment is neuroprotective in various models of status epilepticus (SE) and delays the development of kindling via mechanisms that are assumed to relate to the elevation of GABA levels in the brain." | 3.71 | Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats. ( Halonen, T; Nissinen, J; Pitkänen, A, 2001) |
| " Treatment of epilepsy with vigabatrin (VGB) exemplifies these problems." | 3.71 | Adverse events in medical management--vigabatrin as a paradigm of forensic responsibility with novel therapy. ( Beran, RG, 2001) |
| "Sixty adult patients with partial epilepsy who have been treated with vigabatrin for 7 months to 14 years as mono- or add-on therapy were examined with repeated kinetic Goldmann perimetries to evaluate the prevalence, risk factors, and long-term outcome of vigabatrin-associated visual field defects." | 3.71 | No reversion in vigabatrin-associated visual field defects. ( Kälviäinen, R; Mäntyjärvi, M; Nousiainen, I, 2001) |
| "Using [11C]flumazenil (FMZ)-positron emission tomography (PET) imaging, 15 children (aged 1-8 years) with medically intractable epilepsy were studied." | 3.71 | Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy. ( Chugani, DC; Chugani, HT; Janisse, J; Juhász, C; Muzik, O; Shen, C, 2001) |
| "Vigabatrin use in some epilepsy patients has been associated with persistent visual field constriction and retinal dysfunction." | 3.71 | GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects. ( Felice, K; Hisama, FM; Lee, HH; Mattson, RH; Petroff, OA, 2001) |
| " In the last decade, pregnancy registries have been activated by collaborative groups of physicians in Europe (EURAP), North America (NAREP), Australia and India (the latter two recently merged into EURAP), to enroll a large number of exposed women to be monitored prospectively with standardized methods, and by three pharmaceutical companies marketing lamotrigine, gabapentin and vigabatrin, as part of their post-marketing surveillance." | 3.71 | Pregnancy registries in epilepsy. ( Annegers, JF; Beghi, E, 2001) |
| "Twenty patients with localisations related epilepsy of whom one half had received vigabatrin were subjected to examination without informing about the treatment given." | 3.71 | Vigabatrin and retinal changes. ( Gram, L; Jensen, H; Sjö, O; Uldall, P, 2002) |
| "New antiepileptic drugs designed for enhancing GABAergic inhibition, such as vigabatrin (VGB) may be effective in Angelman syndrome (AS), because associated convulsions could be related to a reduced GABA-receptor density or receptor abnormality." | 3.70 | Adverse effects of vigabatrin in Angelman syndrome. ( Boltshauser, E; Kuenzle, C; Schmitt, B; Steinlin, M; Wohlrab, G, 1998) |
| "This report describes the long-term follow-up of 56 patients with refractory partial epilepsy who, within 3 months of vigabatrin add-on therapy (3 g/day), showed a reduction in monthly seizure frequency of more than 50%." | 3.70 | Long-term treatment with vigabatrin - 10 years of clinical experience. ( Mumford, JP; Riekkinen, PJ; Salmenperä, T; Ylinen, A, 1999) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 3.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "Thirty three unselected patients attending neurology and epilepsy clinics were identified as taking vigabatrin and asked to attend for neuro-ophthalmic evaluation." | 3.70 | Visual field defects associated with vigabatrin therapy. ( Degg, C; Eke, T; Harding, GF; Lawden, MC; Wild, JM, 1999) |
| "21 consecutive patients who had taken vigabatrin at some time in their lives were enrolled from the epilepsy clinic of the Royal Shrewsbury Hospital and were compared with a group of 11 otherwise similar patients with epilepsy who had never received vigabatrin." | 3.70 | A controlled study of vigabatrin and visual abnormalities. ( Goodman, S; Manuchehri, K; Nightingale, S; Siviter, L, 2000) |
| "Epilepsy patients treated with vigabatrin may develop symptomatic or asymptomatic concentric visual field constriction due to GABA-associated retinal dysfunction." | 3.70 | Recovery of visual field constriction following discontinuation of vigabatrin. ( Fish, DR; Holder, G; Krakow, K; MacLeod, WN; Polizzi, G; Riordan-Eva, P, 2000) |
| "A nonrandomly selected cohort of 8 previous and 18 current vigabatrin users and a reference cohort of 8 never vigabatrin-treated patients with epilepsy receiving other antiepilepsy drugs (AED) underwent electro-oculography (EOG), electroretinography (ERG), and automated static threshold perimetry." | 3.70 | Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. ( Harding, GF; Martinez, C; Rietbrock, S; Robertson, KA; Wild, JM, 2000) |
| "Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989." | 3.70 | Vigabatrin-associated visual field defects in children. ( Mackey, DA; Russell-Eggitt, IM; Taylor, DS; Timms, C; Walker, JW, 2000) |
| "One hundred and twenty-seven patients with uncontrolled epilepsy have been treated in an open add-on study with vigabatrin with a mean follow up of ten months." | 3.69 | Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group. ( Russ, W, 1995) |
| "To determine the efficacy of a new anti-epileptic medication vigabatrin in adults and children with drug-resistant epilepsy." | 3.69 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "In an retrospective uncontrolled long-term study in 30 children with intractable epilepsy, it was found that treatment with vigabatrin resulted in a seizure reduction of more than 50% at 1-year follow-up in 40% of the children." | 3.69 | Vigabatrin in childhood epilepsy: a 5-year follow-up study. ( Alving, J; Gram, L; Høgenhaven, H; Uldall, P, 1995) |
| "The purpose of this study was to measure changes in brain GABA after a single oral dose (50 mg/kg) of vigabatrin in patients with intractable epilepsy." | 3.69 | Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. ( Behar, KL; Collins, TL; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 3.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described." | 3.69 | Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). ( Bird, JM; Lambert, MV, 1997) |
| "The relationship between the ratio of vigabatrin concentration to dosage (VGB C/D) and both patient age and the presence of other antiepileptic drugs (AEDs) was analyzed retrospectively by bivariate and multivariate methods in 179 patients with epilepsy (114 children and 65 adults)." | 3.69 | Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs. ( Armijo, JA; Arteaga, R; Bravo, J; Cuadrado, A, 1997) |
| "5 months of pregnancy then carbamazepine 400 mg LP x 2/day, raised to 600 mg LP x 2/day at the 25th week of gestation because of epileptic crisis." | 3.69 | [Carbamazepine and vigabatrin in epileptic pregnant woman and side effects in the newborn infant]. ( Aboulghit, H; Beust, M; Kayemba Kay'S, S; Mourtada, A; Voisin, M, 1997) |
| "A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales." | 3.69 | A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. ( Gordon, GS; Schapel, GJ; Wallace, SJ, 1997) |
| "The possibility that vigabatrin (VGB) decreases serum phenytoin (PHT) concentration by lowering the oral bioavailability of PHT was investigated in 21 patients with epilepsy." | 3.68 | Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. ( Bartoli, A; Gatti, G; Marchiselli, R; Michelucci, R; Perucca, E; Pisani, F; Richens, A; Tassinari, CA; Timmings, P; Zaccara, G, 1993) |
| "We studied the CSF amino acid levels of 42 patients with newly diagnosed epilepsy before treatment with antiepileptic medication and during monotherapy with either vigabatrin or carbamazepine." | 3.68 | Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. ( Halonen, T; Kälviäinen, R; Pitkänen, A; Riekkinen, PJ, 1993) |
| "The effect of introducing vigabatrin into the management of 57 patients with severe epilepsy is reported." | 3.68 | Vigabatrin: a three year clinical analysis. ( Martin, PJ; Millac, PA, 1993) |
| "The long-term clinical, neurophysiologic, and psychological effects of add-on vigabatrin treatment were evaluated in a group of 36 mentally handicapped patients with drug-refractory epilepsy." | 3.68 | Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients. A 5-year follow-up study. ( Luukkainen, R; Matilainen, R; Mervaala, E; Pitkänen, A; Riekkinen, PJ; Ruutiainen, T; Seppänen, R; Ylinen, A, 1993) |
| "Twenty-five patients with epilepsy (mostly with partial seizures) who had responded favourably to a short-term trial of add-on vigabatrin entered maintenance treatment." | 3.68 | Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. ( Galimberti, CA; Iudice, A; Manni, R; Morini, R; Mumford, JP; Perucca, E; Tartara, A, 1992) |
| "Three large studies, all including more than 60 children, on the efficacy on gamma-vinyl GABA (vigabatrin, GVG) in the treatment of childhood epilepsy have been reviewed." | 3.68 | Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin). ( Dulac, O; Gram, L; Sabers, A, 1992) |
| "We report a series of 14 cases of psychosis occurring in patients with severe intractable epilepsy, following the prescription of vigabatrin, a new antiepileptic drug." | 3.68 | Vigabatrin and psychosis. ( Hart, YM; Sander, JW; Shorvon, SD; Trimble, MR, 1991) |
| " Vigabatrin, 50 mg kg-1, was administered orally as add-on therapy to 11 patients with drug-resistant complex partial epilepsy as a single dose, then once every third day for 2 months, every other day for 2 months and daily for 1 month." | 3.67 | The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. ( Ben-Menachem, E; Dahlgren, L; Haegele, KD; Hardenberg, J; Huebert, N; Mumford, JP; Persson, LI; Schechter, PJ, 1989) |
| " Antiepileptic drugs such as vigabatrin [gamma vinyl GABA (GVG)], a drug rationally developed to treat resistant epilepsy, can enhance GABA transmission in these regions and may thereby afford seizure protection." | 3.67 | GABA in epilepsy: the pharmacologic basis. ( Gale, K, 1989) |
| " This study presents the results of the preliminary screening of vigabatrin as add-on therapy in an open, non-controlled multicentre study in children with refractory epilepsy." | 3.67 | Vigabatrin in the treatment of epilepsy in children. ( Aicardi, J; Arzimanoglou, A; Beaumont, D; Livingston, JH, 1989) |
| " The anticonvulsant potency of vigabatrin (gamma-vinyl GABA, GVG) was studied in an open trial in a group of 21 mentally handicapped patients with drug-resistant epilepsy." | 3.67 | Vigabatrin in epilepsy in mentally retarded patients. ( Matilainen, R; Mervaala, E; Pitkänen, A; Riekkinen, P; Ruutiainen, T, 1989) |
| "In studies spanning more than 5 years, more than 1,100 patients with epilepsy have been treated with vigabatrin (gamma vinyl GABA, GVG)." | 3.67 | Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy. ( Dam, M, 1989) |
| "Levels of total gamma-aminobutyric acid (TGABA), free GABA (FGABA), and homocarnosine (HC) were studied in CSF taken from 12 controls and 28 patients with drug-refractory epilepsy before and during 7 months of gamma-vinyl-GABA (GVG) administration." | 3.67 | Levels of total gamma-aminobutyric acid (GABA), free GABA and homocarnosine in cerebrospinal fluid of epileptic patients before and during gamma-vinyl-GABA (vigabatrin) treatment. ( Matilainen, R; Pitkänen, A; Riekkinen, P; Ruutiainen, T, 1988) |
| "We studied the antiepileptic potency of vigabatrin (gamma-vinyl GABA, GVG) as an open trial in a group of 36 mentally handicapped patients with drug-resistant epilepsy (30 had seizures of partial onset and 6 had primary generalized [PG] tonic-clonic convulsions)." | 3.67 | Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study. ( Matilainen, R; Mervaala, E; Pitkänen, A; Riekkinen, P; Ruutiainen, T; Sarlund, H, 1988) |
| "The better and earlier the seizure control, the better the child's subsequent cognitive and behavioral prognosis." | 2.82 | Overview of therapeutic options for epilepsy. ( Chiron, C; Kuchenbuch, M; Milh, M, 2022) |
| "Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity." | 2.71 | The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. ( Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2005) |
| "Vigabatrin (VGB) is a new antiepileptic drug that increases the human brain gamma-aminobutyric acid (GABA) level by irreversibly inhibiting GABA transaminase." | 2.70 | Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. ( Boesiger, P; Duc, CO; Meier, D; Mueller, SG; Russ, W; Weber, B; Weber, OM; Wieser, HG, 2001) |
| "Vigabatrin (VGB) has been shown to cause visual field constriction and other forms of mild visual dysfunction." | 2.70 | Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. ( Johnson, MA; Krauss, GL; Medura, MT; Miller, NR; Miller, TA; Paul, SR, 2001) |
| "Vigabatrin (VGB) has been approved in Europe and is prescribed for either once or twice-daily administration." | 2.69 | Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study. ( Blankenhorn, V; Krämer, G; Mumford, JP; Richens, A; Stefan, H; Thümler, R; Zahner, B, 1999) |
| " We evaluated the cognitive and quality-of-life (QOL) effects of VGB in a double-blinded, add-on, placebo-controlled, parallel group dose-response study of patients with focal epilepsy whose complex partial seizures (CPS) were difficult to control." | 2.68 | Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. ( Arnett, JL; Dodrill, CB; Sommerville, KW; Sussman, NM, 1995) |
| "Vigabatrin (VGB) is an effective add-on anti-epileptic drug." | 2.68 | Retrospective study of vigabatrin and psychiatric behavioural disturbances. ( Wong, IC, 1995) |
| "Vigabatrin was most effective in cryptogenic and symptomatic partial seizures (39% and 43%, respectively), and in infantile spasms (25%)." | 2.68 | Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. ( Coppola, G; Pascotto, A; Terraciano, AM, 1997) |
| "To date, 27 children with partial epilepsy, two with generalized epilepsy, two with Lennox-Gastaut syndrome, and one with nonclassifiable epilepsy have been enrolled in the trial." | 2.67 | Vigabatrin in pediatric epilepsy--an open study. ( Alving, J; Beck, S; Gram, L; Uldall, P, 1991) |
| "Twenty children aged 2 months to 18 years were included in a dose-response study of vigabatrin as add-on therapy to preexisting antiepileptic drugs (up to two per patient)." | 2.67 | Dose-response study of vigabatrin in children with refractory epilepsy. ( Armijo, JA; Arteaga, R; Beaumont, D; Farr, IN; Herranz, JL; Valdizan, E, 1991) |
| "Vigabatrin is a selective, irreversible suicide inhibitor of GABA transaminase and thus increases brain and CSF GABA." | 2.67 | Vigabatrin: rational treatment for chronic epilepsy. ( Farr, IN; Heller, AJ; Reynolds, EH; Ring, HA, 1990) |
| " Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing." | 2.66 | Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020) |
| "The first one is represented by West Syndrome (WS): ES occur in a previously non encephalopathic infant in association with the development of a hypsarrhythmic EEG pattern." | 2.66 | Three different scenarios for epileptic spasms. ( Fusco, L; Santarone, ME; Serino, D, 2020) |
| "1." | 2.66 | A multicentre study of vigabatrin for drug-resistant epilepsy. ( Ben-Menachem, E; Browne, TR; Mattson, RH; Miketta, RM; Penry, JK; Sherry, KM; Smith, DB; Szabo, GK; Treiman, DM; Wilder, BJ, 1989) |
| " Significant inhibition of the platelet GABA-T was produced by treatment with all three doses and a dose-response relationship was demonstrated." | 2.66 | Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug. ( Kongola, G; Richens, A; Rimmer, E, 1988) |
| "Vigabatrin was found to have a frequent and irreversible retinal toxicity, which required an alternative visual testing to be detected in young children." | 2.53 | Stiripentol and vigabatrin current roles in the treatment of epilepsy. ( Chiron, C, 2016) |
| "The mainstay of treatment for infantile spasms is adrenocorticotropic hormone; however, vigabatrin, a vinyl derivative of γ-aminobutyric acid, has been used for the treatment of infantile spasms in Europe since 1989." | 2.47 | Vigabatrin for infantile spasms. ( Belliveau, P; Pesaturo, KA; Spooner, LM, 2011) |
| "Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS." | 2.44 | Vigabatrin. ( Collins, SD; Ramsay, RE; Wheless, JW, 2007) |
| " For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable." | 2.43 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006) |
| "The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions." | 2.42 | The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003) |
| "Vigabatrin (VGB) is a new antiepileptic drug, that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase." | 2.42 | [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy]. ( Bakunowicz-Łazarczyk, A; Mrugacz, M, 2003) |
| " So the search for more effective drugs with minimal adverse effect profiles will continue." | 2.42 | Adverse effects of new antiepileptic drugs. ( Onat, F; Ozkara, C, 2004) |
| "Vigabatrin has shown promise in treating IS patients, particularly those with tuberous sclerosis." | 2.42 | Pharmacologic treatment of the catastrophic epilepsies. ( Conry, JA, 2004) |
| "Vigabatrin has been shown to be particularly effective in treating infantile spasms in the setting of tuberous sclerosis complex." | 2.42 | Managing epilepsy in tuberous sclerosis complex. ( Thiele, EA, 2004) |
| "Vigabatrin is a GABA (gamma-aminobutyric acid) transaminase inhibitor that elicits an antiepileptic effect by enhancing inhibitory neurotransmission in the brain." | 2.41 | Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance. ( Hilton, EJ; Hosking, SL, 2002) |
| " However, on rare occasions, they can progress to more severe cutaneous disorders, including Stevens-Johnson syndrome and toxic epidermal necrolysis." | 2.41 | Therapeutic safety monitoring: what to look for and when to look for it. ( Harden, CL, 2000) |
| "Vigabatrin (VGB) is a new antiepileptic drug useful in refractOry partial seizures." | 2.41 | [Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy] . ( García Pastor, A; García-Zarza, E; Peraita Adrados, R, 2000) |
| " Corticotropin (adrenocorticotropic hormone) or corticosteroids have been the gold standard treatment for the last 40 years, but there is little agreement on the best agent to use, or the dosage and duration of the treatment." | 2.41 | A risk-benefit assessment of treatments for infantile spasms. ( Nabbout, R, 2001) |
| "Standard antiepileptic drugs (AEDs) have a number of pharmacokinetic shortcomings, and AEDs with more favorable profiles would be preferred." | 2.40 | Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. ( Johannessen, SI, 1997) |
| "Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management." | 2.40 | Overview of the safety of newer antiepileptic drugs. ( Shorvon, S; Stefan, H, 1997) |
| "Vigabatrin is a structural analogue of gamma amino butyric acid (GABA), which binds irreversibly to GABA-transaminase causing increased brain levels of GABA." | 2.40 | Vigabatrin. ( Sankar, R; Shields, WD, 1997) |
| "Felbamate, however, has been linked with substantially increased incidence of aplastic anemia, and the other new AEDs have been studied for relatively short periods of time." | 2.40 | Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. ( Chapman, DP; Giles, WH, 1997) |
| "Gamma-aminobutyric acid (GABA) plays a pivotal role in suppressing the origin and spread of seizure activity." | 2.40 | Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. ( Petroff, OA; Rothman, DL, 1998) |
| " Because dosing is often modest, cost should rarely be the overriding factor in choosing a drug for a patient with newly diagnosed epilepsy in the developed world." | 2.40 | Monostars: an aid to choosing an antiepileptic drug as monotherapy. ( Brodie, MJ, 1999) |
| "To most effectively treat children with epilepsy syndromes, further research must be completed to validate the positive effects described in case reports, open-label clinical trials, and early controlled clinical trials." | 2.40 | Managing pediatric epilepsy syndromes with new antiepileptic drugs. ( Pellock, JM, 1999) |
| " Pharmacodynamic interactions take place at the level of receptor sites, where they may have additive or potentiating effects." | 2.39 | Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. ( Richens, A, 1995) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 2.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Epilepsy is one of the most common neurological disorders." | 2.39 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994) |
| "Vigabatrin was designed to increase the levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain." | 2.39 | A risk-benefit assessment of vigabatrin in the treatment of neurological disorders. ( Richens, A; Srinivasan, J, 1994) |
| "Vigabatrin (VGB, Sabril) is a new antiepileptic drug used for treatment of partial and secondarily generalized tonic-clonic seizures." | 2.39 | Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. ( Behar, K; Mattson, RH; Petroff, O; Rothman, D, 1994) |
| " ZNS daily dosage is 400-600 mg." | 2.39 | Antiepileptic drugs in development: prospects for the near future. ( Leppik, IE, 1994) |
| "Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions." | 2.39 | Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. ( Perucca, E, 1996) |
| "gamma-Aminobutyric acid (GABA) was first proposed as a putative inhibitory neurotransmitter by Elliot and van Gelder in 1958." | 2.39 | Vigabatrin. ( Ben-Menachem, E, 1995) |
| " Adverse effects of antiepileptic treatment may affect the patient's quality of life to an even greater extent than the occurrence of seizures." | 2.39 | Adverse effects of established and new antiepileptic drugs: an attempted comparison. ( Gram, L; Rogvi-Hansen, B, 1995) |
| " However, the pharmacokinetic properties of an AED determine its ease of use, i." | 2.39 | Important pharmacokinetic properties of antiepileptic drugs. ( Bourgeois, BF, 1995) |
| " This may be related to dosage and speed of introduction." | 2.39 | Psychotic and severe behavioural reactions with vigabatrin: a review. ( Ferrie, CD; Panayiotopoulos, CP; Robinson, RO, 1996) |
| "This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin." | 2.39 | Pharmacokinetics of new antiepileptic drugs. ( Gram, L, 1996) |
| "Epilepsy is common in individuals who are mentally retarded and/or otherwise multiply handicapped." | 2.39 | The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. ( Mattson, RH, 1996) |
| "For many years, the medical treatment of epilepsy was based on the use of the same few drugs, which were chosen according to the seizure type in a fairly standardized manner." | 2.39 | New antiepileptic drugs. ( Bourgeois, BF, 1996) |
| "Vigabatrin is an irreversible inhibitor of GABA transaminase." | 2.39 | [Antiepileptic drugs: mechanism of action]. ( Mercadé Cerdá, JM, 1996) |
| " Specific indications and dosage schedules have been provided." | 2.39 | New antiepileptic drugs. ( Brodie, MJ; Wilson, EA, 1996) |
| "Epilepsy is a common condition with a prevalence of just 1% in a given population." | 2.39 | New drugs and vagal stimulation for treatment of epilepsy--the Israeli experience. ( Korczyn, AD; Neufeld, MY, 1996) |
| "Epilepsy is a disorder of the central nervous system in which the clinical symptoms are recurrent seizures." | 2.38 | Advances in pharmacotherapy: recent developments in the treatment of epilepsy. ( Graves, NM; Leppik, IE, 1993) |
| "Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 2.38 | Vigabatrin. Clinical pharmacokinetics. ( Olive, G; Pons, G; Rey, E, 1992) |
| "Vigabatrin is an enzyme-activated, irreversible inhibitor of gamma-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action." | 2.38 | Pharmacology and clinical pharmacology of vigabatrin. ( Richens, A, 1991) |
| "Epileptic spasms were asymmetric in three patients and unilateral in two." | 1.72 | Status of epileptic spasms: A study of 21 children. ( Buompadre, C; Caraballo, R; Chacón, S; Fasulo, L; Gallo, A; Reyes, G; Semprino, M, 2022) |
| "Vigabatrin is a preferred drug in patients younger than two years old for both focal (61." | 1.62 | Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. ( Fladrowski, C; Jóźwiak, S; Kotulska, K; Roberds, SL; Szymańska, S; Słowińska, M, 2021) |
| "An epilepsy mouse model for Tuberous Sclerosis Complex (TSC) was developed and validated to investigate the mechanisms underlying epileptogenesis." | 1.51 | Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model. ( Elgersma, Y; Koene, LMC; Kooijman, NHRM; Proietti Onori, M; Schreiber, J; van Grondelle, SE; van Oort, A; Wallaard, I, 2019) |
| "Vigabatrin is a highly effective antiseizure medication, but its use is limited due to concerns about retinal toxicity." | 1.43 | Plasma taurine levels are not affected by vigabatrin in pediatric patients. ( Mabud, TS; Porter, BE; Reimer, R; Spelbrink, EM, 2016) |
| "Valproic acid was prescribed most frequently as first and second treatment, followed by vigabatrin." | 1.42 | Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. ( Bindels-de Heus, K; de Wit, MC; Moll, HA; Overwater, IE; Rietman, AB; Ten Hoopen, LW; Vergouwe, Y, 2015) |
| "Vigabatrin is an antiepileptic drug that results in higher gamma-aminobutyrate levels in the brain and retina." | 1.40 | Electroretinographic responses in epileptic children treated with vigabatrin. ( Ashrafi, MR; Bakhshandeh Bali, MK; Ghofrani, M; Karimzadeh, P; Nasehi, MM; Otaghsara, SM; Sadighi, N; Soltansanjari, M; Taghdiri, MM, 2014) |
| "The ultimate treatment goal in epilepsy therapy is always freedom from seizures with as few treatment adverse effects as possible." | 1.40 | Medical management of refractory epilepsy--practical treatment with novel antiepileptic drugs. ( Ben-Menachem, E, 2014) |
| "Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase." | 1.40 | Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ( Karim, A; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2014) |
| "Introduccion." | 1.39 | [Characterisation of the paediatric population of Costa Rica with tuberous sclerosis and a description of the behaviour of the associated epilepsy]. ( Benavides-Lara, A; Hernández, L; Ulate-Campos, A, 2013) |
| "Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation." | 1.38 | Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. ( Backofen-Wehrhahn, B; Bankstahl, M; Bröer, S; Gernert, M; Gey, L; Löscher, W, 2012) |
| "Vigabatrin has been shown to be particularly effective in treating infantile spasms in the setting of tuberous sclerosis." | 1.38 | [The course and treatment of epilepsy in children with tuberose sclerosis]. ( Belousova, ED; Dorofeeva, MIu, 2012) |
| "Vigabatrin is an antiepileptic drug that produces intramyelinic edema in several animal models." | 1.35 | Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. ( Bartoli, C; Chabrol, B; Chapon, F; Girard, N; Hugonenq, C; Lamoureux, S; Livet, MO; Mancini, J; Milh, M; Pineau, S; Villeneuve, N, 2009) |
| "Epileptic seizures can be difficult to recognize in infancy and childhood because the semeiology can be misleading." | 1.35 | [Epileptic seizures in childhood: from seizure type to diagnosis]. ( Chabrol, B; Hugonencq, C; Mancini, J; Milh, M; Ticus, I; Villeneuve, N, 2008) |
| "Vigabatrin has proved to be effective against infantile spasms due to TSC." | 1.35 | Management of epilepsy in tuberous sclerosis complex. ( Bombardieri, R; Cerminara, C; Curatolo, P; D'Argenzio, L, 2008) |
| "Vigabatrin (VGB) is an important treatment option for infantile spasms." | 1.33 | Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero. ( Heinonen, S; Herrgård, E; Kälviäinen, R; Pääkkönen, A; Sorri, I; Viinikainen, K, 2005) |
| "Vigabatrin was anticonvulsant in all groups for up to 13 days with a maximal effect 24 h after injection." | 1.32 | The central piriform cortex: anatomical connections and anticonvulsant effect of GABA elevation in the kindling model. ( Ebert, U; Löscher, W; Schwabe, K, 2004) |
| "The diagnostic criteria for tuberous sclerosis complex (TSC) have recently been revised." | 1.32 | Spectrum of epilepsy in tuberous sclerosis. ( Anisya-Vasanth, AV; Jayakumar, PN; Nagaraja, D; Satishchandra, P; Swamy, HS, 2004) |
| " The mean values of pharmacokinetic parameters were: level/dose ratio (L/D) = 0." | 1.31 | Effect of vigabatrin on the pharmacokinetics of carbamazepine. ( Llopis, P; López, E; Quintana, MB; Rodríguez, I; Sánchez-Alcaraz, A, 2002) |
| "1." | 1.31 | [Vigabatrin in the treatment of intractable focal epilepsy in children and adolescents. Two-year study]. ( Grotowska, M; Kozik, A; Ujma-Czapska, B, 2000) |
| " The toxic effect of gamma-vinyl-GABA was mimicked by a 24-h treatment with GABA (100 microM) and the GABA(A) receptor agonist, muscimol (10 microM), but not the GABA(B) receptor agonist, baclofen (10 microM)." | 1.31 | GABA(A)-mediated toxicity of hippocampal neurons in vitro. ( Lukasiuk, K; Pitkänen, A, 2000) |
| "Vigabatrin is an effective antiepileptic drug, but it is known to cause a variety of changes in visual function, including reductions in the visual field, visual acuity, color vision, and in electroretinogram (ERG) and electro-oculogram amplitudes." | 1.31 | Visual function loss from vigabatrin: effect of stopping the drug. ( Johnson, MA; Krauss, GL; Medura, M; Miller, NR; Paul, SR, 2000) |
| "Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms." | 1.31 | Visual impairment in children with epilepsy treated with vigabatrin. ( Banin, E; Gross-Tsur, V; Lahat, E; Shahar, E; Shalev, RS, 2000) |
| "Epilepsy was characterized by status epilepticus or a cluster of seizures." | 1.31 | Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. ( Bellet, H; Echenne, B; Humbertclaude, V; Morin, D; Rivier, F; Roubertie, A; Vallat, C, 2001) |
| "Vigabatrin (VGB) is a gabaergic anti-epileptic medication (AEM) reported to produce tunnel vision with constricted fields." | 1.31 | Ethical dilemmas of potential adverse events. ( Beran, RG, 2001) |
| "Vigabatrin dose was 25-114 mg/kg/day (mean 55." | 1.31 | Vigabatrin associated retinal dysfunction in children with epilepsy. ( Al Riyami, K; Bulusu, S; Chacko, A; Ganesh, A; Koul, R, 2001) |
| "Vigabatrin was discontinued in one-third of the patients on chronic medication (mean duration 4." | 1.31 | Electro-ophthalmological recovery after withdrawal from vigabatrin. ( Graniewski-Wijnands, HS; van der Torren, K, 2002) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Lamotrigine was the only drug which antagonized tonic convulsions in the MES test (ED50 = 36 mumol/kg)." | 1.30 | Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. ( Dalby, NO; Nielsen, EB, 1997) |
| "Length of seizure disorder, seizure frequency at initiation, the number of previously used failed drugs and the total number of drugs previously used were all significantly lower in the seizure-free group." | 1.30 | The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication. ( Kerr, MP; Thijs, RD, 1998) |
| "In 1993, 27% of patients were being treated for epilepsy and in 1995/6, 30." | 1.30 | The management of epilepsy in a hospital for people with a learning disability. ( Carvill, S; Cassidy, G; Clarke, D, 1999) |
| "Vigabatrin was without effect on either pentylenetetrazol- or maximal electroshock-induced seizures, whereas tiagabine increased the latency to pentylenetetrazol seizures and reduced the incidence of maximal electroshock seizures." | 1.30 | Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study. ( Brodie, MJ; Butler, E; Sills, GJ; Thompson, GG, 1999) |
| "Vigabatrin was well tolerated, we did not experience any serous adverse reactions." | 1.30 | [Vigabatrin in childhood epilepsy--personal experience]. ( Buljina, A; Catibusić, F; Gavranović, M; Uzicanin, S; Zubcević, S, 1999) |
| "Vigabatrin (VGB) is an antiepileptic drug (AED) that acts by irreversibly inhibiting gamma-aminobutyric acid transaminase (GABA-T)." | 1.29 | Immunologic aspects of vigabatrin treatment in epileptic children. ( Iannetti, P; Imperato, C; Pacifici, R; Raucci, U; Zuccaro, P, 1995) |
| "Vigabatrin (VGB) is a safe and effective antiepileptic drug (AED) that irreversibly inhibits neuronal and glial GABA-transaminase." | 1.29 | Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain. ( Behar, KL; Mattson, RH; Petroff, OA; Rothman, DL, 1995) |
| "Gabapentin is a gamma-aminobutyric acid (GABA) analog which passes the blood-brain barrier." | 1.29 | [New medical treatment of epilepsy]. ( Loiseau, P, 1996) |
| "Vigabatrin (VGB) is a recently-released antiepileptic drug which works by a clearly-defined mechanism of action: inhibition of GABA transaminase leading to an elevation of brain GABA concentration." | 1.29 | Vigabatrin. ( Guberman, A, 1996) |
| " The results show that whether or not the introduction of vigabatrin results in an increase or a reduction in costs to the healthcare system depends largely on 3 factors: (i) the administered dosage of vigabatrin; (ii) the effect that vigabatrin has on hospital admissions; and (iii) the proportion of epileptic patients who take the drug." | 1.29 | The economic effects of introducing vigabatrin, a new antiepileptic medication. ( Champagne, F; Contandriopoulos, AP; Kennedy, W; Reinharz, D; Tessier, G, 1995) |
| "Vigabatrin is a new antiepileptic drug that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase." | 1.28 | Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. ( Butler, WH; Cannon, DJ; Lewis, PJ; Mumford, JP, 1991) |
| " In group I, the half-life of the R(-) isomer was significantly shorter than that of the S(+) isomer; in group II, the half-lives were comparable." | 1.28 | Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ( Beaumont, D; Chiron, C; D'Athis, P; Dulac, O; Olive, G; Pons, G; Rey, E; Richard, MO; Vauzelle, F, 1990) |
| "1." | 1.28 | Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. ( Beaumont, D; Chauvel, P; Gisselbrecht, D; Liegeois-Chauvel, C; Marquis, P; Pantieri, R, 1989) |
| "Epilepsy is not a benign condition." | 1.28 | gamma Vinyl GABA: current role in the management of drug-resistant epilepsy. ( Treiman, DM, 1989) |
| "gamma-Vinyl GABA (GVG), an irreversible inhibitor of GABA degradation, was administered to seizure-susceptible gerbils at different dosage regimens." | 1.27 | One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels. ( Frey, HH; Löscher, W, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (9.76) | 18.7374 |
| 1990's | 192 (42.57) | 18.2507 |
| 2000's | 137 (30.38) | 29.6817 |
| 2010's | 53 (11.75) | 24.3611 |
| 2020's | 25 (5.54) | 2.80 |
| Authors | Studies |
|---|---|
| Hawker, DD | 1 |
| Silverman, RB | 2 |
| Golec, W | 1 |
| Sołowiej, E | 1 |
| Strzelecka, J | 1 |
| Jurkiewicz, E | 1 |
| Jóźwiak, S | 10 |
| D'Gama, AM | 1 |
| Poduri, A | 1 |
| Feja, M | 1 |
| Meller, S | 1 |
| Deking, LS | 1 |
| Kaczmarek, E | 1 |
| During, MJ | 1 |
| Gernert, M | 2 |
| Caraballo, R | 1 |
| Semprino, M | 1 |
| Fasulo, L | 1 |
| Reyes, G | 1 |
| Chacón, S | 1 |
| Gallo, A | 1 |
| Buompadre, C | 1 |
| Wang, X | 1 |
| Ding, Y | 1 |
| Zhou, Y | 2 |
| Yu, L | 1 |
| Zhou, S | 1 |
| Wang, Y | 1 |
| Wang, J | 3 |
| Ramantani, G | 1 |
| Bölsterli, BK | 1 |
| Alber, M | 1 |
| Klepper, J | 1 |
| Korinthenberg, R | 2 |
| Kurlemann, G | 1 |
| Tibussek, D | 1 |
| Wolff, M | 1 |
| Schmitt, B | 3 |
| Giuliano, L | 1 |
| Vecchio, C | 1 |
| Mastrangelo, V | 1 |
| Durante, V | 1 |
| Zambrelli, E | 1 |
| Cantalupo, G | 1 |
| La Neve, A | 1 |
| Ermio, C | 1 |
| Mostacci, B | 1 |
| Tomson, T | 2 |
| Battino, D | 1 |
| Bromley, R | 1 |
| Kochen, S | 3 |
| Meador, KJ | 1 |
| Pennell, PB | 1 |
| Thomas, SV | 1 |
| Kuchenbuch, M | 1 |
| Chiron, C | 10 |
| Milh, M | 3 |
| de Saint Martin, A | 1 |
| Napuri, S | 1 |
| Nguyen, S | 1 |
| Osborne, JP | 2 |
| Edwards, SW | 2 |
| Alber, FD | 1 |
| Hancock, E | 2 |
| Johnson, AL | 2 |
| Kennedy, CR | 2 |
| Likeman, M | 1 |
| Lux, AL | 2 |
| Mackay, M | 2 |
| Mallick, A | 1 |
| Newton, RW | 2 |
| Nolan, M | 1 |
| Pressler, R | 1 |
| Rating, D | 1 |
| Verity, CM | 2 |
| O'Callaghan, FK | 1 |
| Riikonen, R | 2 |
| Pong, AW | 1 |
| Xu, KJ | 1 |
| Klein, P | 3 |
| Sampaio, LPB | 1 |
| Henriques-Souza, AMM | 1 |
| Silveira, MRMD | 1 |
| Seguti, L | 1 |
| Santos, MLSF | 1 |
| Montenegro, MA | 1 |
| Antoniuk, S | 1 |
| Manreza, MLG | 1 |
| Huschner, F | 1 |
| Głowacka-Walas, J | 2 |
| Mills, JD | 1 |
| Klonowska, K | 1 |
| Lasseter, K | 1 |
| Asara, JM | 1 |
| Moavero, R | 6 |
| Hertzberg, C | 4 |
| Weschke, B | 4 |
| Riney, K | 4 |
| Feucht, M | 4 |
| Scholl, T | 2 |
| Krsek, P | 4 |
| Nabbout, R | 6 |
| Jansen, AC | 4 |
| Petrák, B | 1 |
| van Scheppingen, J | 1 |
| Zamecnik, J | 1 |
| Iyer, A | 1 |
| Anink, JJ | 1 |
| Mühlebner, A | 1 |
| Mijnsbergen, C | 1 |
| Lagae, L | 4 |
| Curatolo, P | 9 |
| Borkowska, J | 4 |
| Sadowski, K | 4 |
| Domańska-Pakieła, D | 5 |
| Blazejczyk, M | 1 |
| Jansen, FE | 3 |
| Janson, S | 1 |
| Urbanska, M | 1 |
| Tempes, A | 1 |
| Janssen, B | 1 |
| Sijko, K | 3 |
| Wojdan, K | 4 |
| Kotulska, K | 7 |
| Lehmann, K | 1 |
| Aronica, E | 4 |
| Jaworski, J | 1 |
| Kwiatkowski, DJ | 4 |
| Słowińska, M | 2 |
| Łojszczyk, B | 1 |
| Chmielewski, D | 1 |
| Kaczorowska-Frontczak, M | 2 |
| Głowacka, J | 1 |
| Hussain, SA | 1 |
| Asilnejad, B | 1 |
| Heesch, J | 1 |
| Navarro, M | 1 |
| Ji, M | 1 |
| Shrey, DW | 1 |
| Rajaraman, RR | 1 |
| Sankar, R | 2 |
| Friedman, A | 1 |
| Hameed, MQ | 1 |
| Kaminski, RM | 1 |
| Bar-Klein, G | 1 |
| Klitgaard, H | 1 |
| Koepp, M | 1 |
| Prince, DA | 1 |
| Rotenberg, A | 1 |
| Twyman, R | 2 |
| Vezzani, A | 1 |
| Wong, M | 1 |
| Löscher, W | 6 |
| Kharytonov, V | 1 |
| Dulac, O | 8 |
| Ji, X | 2 |
| Wright, T | 2 |
| VandenHoven, C | 1 |
| MacKeen, L | 1 |
| McFarlane, M | 2 |
| Liu, H | 2 |
| Dupuis, A | 2 |
| Westall, C | 1 |
| Benvenuto, A | 1 |
| Emberti Gialloreti, L | 1 |
| Van Schooneveld, MM | 1 |
| Samueli, S | 2 |
| Maulisovà, A | 1 |
| Jansen, F | 1 |
| Hulshof, H | 1 |
| Benova, B | 2 |
| de Ridder, J | 2 |
| Fusco, L | 1 |
| Serino, D | 1 |
| Santarone, ME | 1 |
| Szymańska, S | 1 |
| Roberds, SL | 1 |
| Fladrowski, C | 1 |
| Verhelle, B | 1 |
| Vervisch, J | 1 |
| Lemmens, K | 1 |
| Ferrier, CH | 1 |
| French, JA | 2 |
| Bebin, M | 1 |
| Dichter, MA | 1 |
| Engel, J | 1 |
| Hartman, AL | 1 |
| McNamara, J | 1 |
| Vespa, P | 1 |
| Peng, Y | 1 |
| Zhao, Y | 1 |
| Hu, W | 1 |
| Hu, Y | 1 |
| He, Y | 1 |
| Tuğcu, B | 1 |
| Bitnel, MK | 1 |
| Kaya, FS | 1 |
| Güveli, BT | 1 |
| Ataklı, D | 1 |
| Jackson, MC | 1 |
| Jafarpour, S | 1 |
| Klehm, J | 1 |
| Thome-Souza, S | 1 |
| Coughlin, F | 1 |
| Kapur, K | 1 |
| Loddenkemper, T | 1 |
| Zuberi, SM | 1 |
| Brunklaus, A | 1 |
| van der Poest Clement, EA | 1 |
| Sahin, M | 2 |
| Peters, JM | 2 |
| Westall, CA | 3 |
| Wild, JM | 8 |
| Smith, PEM | 1 |
| Knupp, C | 1 |
| Koene, LMC | 1 |
| van Grondelle, SE | 1 |
| Proietti Onori, M | 1 |
| Wallaard, I | 1 |
| Kooijman, NHRM | 1 |
| van Oort, A | 1 |
| Schreiber, J | 1 |
| Elgersma, Y | 1 |
| Clayton, LM | 4 |
| Stern, WM | 1 |
| Newman, WD | 1 |
| Sander, JW | 10 |
| Acheson, J | 2 |
| Sisodiya, SM | 5 |
| Bakhshandeh Bali, MK | 1 |
| Otaghsara, SM | 1 |
| Soltansanjari, M | 1 |
| Sadighi, N | 1 |
| Nasehi, MM | 1 |
| Ashrafi, MR | 1 |
| Karimzadeh, P | 1 |
| Taghdiri, MM | 1 |
| Ghofrani, M | 1 |
| Treiman, DM | 4 |
| Ulate-Campos, A | 1 |
| Benavides-Lara, A | 1 |
| Hernández, L | 1 |
| Chukwu, J | 1 |
| Delanty, N | 3 |
| Webb, D | 1 |
| Cavalleri, GL | 3 |
| Ben-Menachem, E | 5 |
| Nowomiejska, K | 1 |
| Jedrych, M | 1 |
| Brzozowska, A | 1 |
| Rejdak, K | 1 |
| Zarnowski, T | 1 |
| Koss, MJ | 1 |
| Ksiazek, K | 1 |
| Ksiazek, P | 1 |
| Maciejewski, R | 1 |
| Juenemann, AG | 1 |
| Schiefer, U | 3 |
| Rejdak, R | 1 |
| Nielsen, JC | 1 |
| Kowalski, KG | 1 |
| Karim, A | 1 |
| Patel, M | 1 |
| Wesche, DL | 2 |
| Tolbert, D | 1 |
| An, I | 1 |
| Davis, PE | 1 |
| Krueger, DA | 1 |
| Overwater, IE | 1 |
| Bindels-de Heus, K | 1 |
| Rietman, AB | 1 |
| Ten Hoopen, LW | 1 |
| Vergouwe, Y | 1 |
| Moll, HA | 1 |
| de Wit, MC | 1 |
| Elterman, RD | 1 |
| Shields, WD | 4 |
| Xiao, Y | 2 |
| Gan, L | 2 |
| Luo, M | 2 |
| Luo, H | 2 |
| Krauss, G | 1 |
| Faught, E | 2 |
| Foroozan, R | 2 |
| Pellock, JM | 7 |
| Sergott, RC | 2 |
| Ziemann, A | 1 |
| Dribinsky, Y | 1 |
| Lee, D | 1 |
| Torri, S | 1 |
| Othman, F | 1 |
| Isojarvi, J | 1 |
| Spelbrink, EM | 1 |
| Mabud, TS | 1 |
| Reimer, R | 1 |
| Porter, BE | 1 |
| Camfield, CS | 1 |
| Andrade, DM | 1 |
| Arzimanoglou, A | 2 |
| Cramer, JA | 2 |
| Kossoff, E | 1 |
| Mula, M | 1 |
| Camfield, PR | 1 |
| Villeneuve, N | 2 |
| Chapon, F | 1 |
| Pineau, S | 1 |
| Lamoureux, S | 1 |
| Livet, MO | 1 |
| Bartoli, C | 1 |
| Hugonenq, C | 1 |
| Mancini, J | 2 |
| Chabrol, B | 2 |
| Girard, N | 1 |
| Franciotta, D | 1 |
| Kwan, P | 1 |
| Perucca, E | 9 |
| Duncan, JS | 3 |
| Acheson, JF | 3 |
| Agrawal, S | 1 |
| Mayer, DL | 1 |
| Hansen, RM | 1 |
| Fulton, AB | 1 |
| Cazorla, MR | 1 |
| Verdú, A | 1 |
| Montes, C | 1 |
| Ayuga, F | 1 |
| Naili, F | 1 |
| Boucart, M | 1 |
| Derambure, P | 1 |
| Arndt, C | 1 |
| Gonzalez, P | 1 |
| Sills, GJ | 2 |
| Parks, S | 1 |
| Kelly, K | 1 |
| Stephen, LJ | 1 |
| Keating, D | 1 |
| Dutton, GN | 1 |
| Brodie, MJ | 8 |
| Rhim, Jw | 1 |
| Yoo, C | 1 |
| Kim, SH | 1 |
| Cavanna, AE | 1 |
| Ali, F | 1 |
| Rickards, HE | 1 |
| McCorry, D | 1 |
| Besag, FM | 1 |
| Sorri, I | 3 |
| Brigell, MG | 2 |
| Mályusz, M | 1 |
| Mahlamäki, E | 1 |
| de Meynard, C | 1 |
| Kälviäinen, R | 7 |
| Navas-Sánchez, P | 1 |
| Martínez-Antón, J | 1 |
| Bauzano-Poley, E | 1 |
| Dévilé, M | 2 |
| Punte, T | 2 |
| Kallis, C | 1 |
| de Haan, GJ | 2 |
| McCoy, B | 1 |
| Weiss, S | 2 |
| Go, C | 1 |
| Pesaturo, KA | 1 |
| Spooner, LM | 1 |
| Belliveau, P | 1 |
| Ohtsuka, Y | 1 |
| Maguire, M | 2 |
| Marson, AG | 5 |
| Ramaratnam, S | 2 |
| Russo, E | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| Urzino, A | 1 |
| Marra, R | 1 |
| Rispoli, V | 1 |
| De Sarro, G | 1 |
| Brodie, SE | 1 |
| Burkhart, GA | 1 |
| Krauss, GL | 5 |
| Weinberg, MA | 1 |
| Cusmai, R | 2 |
| Bombardieri, R | 4 |
| Vigevano, F | 1 |
| Merlin, E | 1 |
| Pereira, B | 1 |
| Nourrissat, A | 1 |
| Bröer, S | 1 |
| Backofen-Wehrhahn, B | 1 |
| Bankstahl, M | 1 |
| Gey, L | 1 |
| Heim, MK | 1 |
| Gidal, BE | 1 |
| Hopkins, CR | 1 |
| Dorofeeva, MIu | 2 |
| Belousova, ED | 2 |
| Nicolson, A | 1 |
| Leach, JP | 3 |
| Chadwick, DW | 5 |
| Smith, DF | 1 |
| Schmidt, T | 3 |
| Rüther, K | 3 |
| Jokiel, B | 2 |
| Pfeiffer, S | 2 |
| Tiel-Wilck, K | 2 |
| Schmitz, B | 3 |
| Hanaya, R | 1 |
| Sasa, M | 1 |
| Kiura, Y | 1 |
| Serikawa, T | 1 |
| Kurisu, K | 1 |
| Hosking, SL | 3 |
| Hilton, EJ | 1 |
| Sánchez-Alcaraz, A | 1 |
| Quintana, MB | 1 |
| López, E | 1 |
| Rodríguez, I | 1 |
| Llopis, P | 1 |
| Roff Hilton, EJ | 1 |
| Embleton, SJ | 1 |
| Gupta, AK | 1 |
| Lawden, MC | 3 |
| Johnson, MA | 3 |
| Sheth, S | 1 |
| Miller, NR | 4 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| Fledelius, HC | 2 |
| Kim, S | 2 |
| Hays, RD | 3 |
| Birbeck, GL | 3 |
| Vickrey, BG | 3 |
| Riise, P | 1 |
| Rogvi-Hansen, Bà | 1 |
| Askalan, R | 1 |
| Brian, J | 1 |
| Otsubo, H | 1 |
| McDermott, C | 1 |
| Bryson, S | 1 |
| Boyd, J | 1 |
| Snead, C | 1 |
| Roberts, W | 1 |
| Harding, GF | 6 |
| Robertson, KA | 3 |
| Holliday, I | 1 |
| Banin, E | 3 |
| Shalev, RS | 2 |
| Obolensky, A | 1 |
| Neis, R | 1 |
| Chowers, I | 1 |
| Gross-Tsur, V | 3 |
| Gosakan, R | 1 |
| von Knorring, N | 1 |
| Stewart, P | 1 |
| Johannessen, SI | 4 |
| Kang, TC | 1 |
| An, SJ | 1 |
| Park, SK | 1 |
| Hwang, IK | 1 |
| Won, MH | 1 |
| Gatti, G | 1 |
| Bartoli, A | 1 |
| Marchiselli, R | 1 |
| Michelucci, R | 2 |
| Tassinari, CA | 2 |
| Pisani, F | 1 |
| Zaccara, G | 1 |
| Timmings, P | 1 |
| Richens, A | 8 |
| Hardus, P | 3 |
| Verduin, W | 1 |
| Berendschot, T | 1 |
| Postma, G | 1 |
| Stilma, J | 1 |
| van Veelen, C | 1 |
| Frisén, L | 1 |
| Mrugacz, M | 2 |
| Bakunowicz-Łazarczyk, A | 2 |
| Mares, P | 2 |
| Slamberová, R | 1 |
| Wu, SP | 1 |
| Shyu, MK | 1 |
| Liou, HH | 1 |
| Gau, CS | 1 |
| Lin, CJ | 1 |
| Parisi, P | 2 |
| Tommasini, P | 1 |
| Piazza, G | 1 |
| Manfredi, M | 1 |
| Schwabe, K | 1 |
| Ebert, U | 1 |
| Onat, F | 1 |
| Ozkara, C | 1 |
| Anisya-Vasanth, AV | 1 |
| Satishchandra, P | 1 |
| Nagaraja, D | 1 |
| Swamy, HS | 1 |
| Jayakumar, PN | 1 |
| Conry, JA | 1 |
| Thiele, EA | 2 |
| Herrgård, E | 1 |
| Viinikainen, K | 1 |
| Pääkkönen, A | 1 |
| Heinonen, S | 1 |
| Selai, CE | 2 |
| Trimble, MR | 5 |
| Price, MJ | 1 |
| Remak, E | 1 |
| Steinborn, B | 1 |
| Rigolet, MH | 1 |
| Baulac, M | 2 |
| Nordmann, JP | 1 |
| O'Callaghan, FJ | 1 |
| Ermakov, AIu | 1 |
| Moreno, MC | 1 |
| Giagante, B | 1 |
| Saidon, P | 1 |
| Benozzi, J | 1 |
| Rosenstein, RE | 1 |
| Kinirons, P | 2 |
| O'Rourke, D | 1 |
| Doherty, CP | 2 |
| Reid, I | 1 |
| Logan, P | 1 |
| Liggan, B | 1 |
| Robson, CR | 1 |
| Jones, AL | 1 |
| Cunliffe, IA | 1 |
| Smith, PE | 1 |
| Cerminara, C | 2 |
| Singh, R | 1 |
| Shahwan, A | 1 |
| Wood, NW | 1 |
| Goldstein, DB | 1 |
| Humphrey, A | 1 |
| Neville, BG | 1 |
| Clarke, A | 1 |
| Bolton, PF | 1 |
| Werth, R | 1 |
| Schädler, G | 1 |
| You, SJ | 1 |
| Ahn, H | 1 |
| Ko, TS | 1 |
| Buoni, S | 2 |
| Zannolli, R | 1 |
| Waterham, H | 1 |
| Wanders, R | 1 |
| Fois, A | 2 |
| Wheless, JW | 1 |
| Ramsay, RE | 2 |
| Collins, SD | 1 |
| Luszczki, JJ | 1 |
| Czuczwar, SJ | 2 |
| Leuzzi, V | 1 |
| Di Sabato, ML | 1 |
| Deodato, F | 1 |
| Rizzo, C | 1 |
| Boenzi, S | 1 |
| Carducci, C | 1 |
| Malaspina, P | 1 |
| Liberanome, C | 1 |
| Dionisi-Vici, C | 1 |
| Ahn, HS | 1 |
| Bursztyn, J | 1 |
| Gandolfo, E | 1 |
| Safran, AB | 1 |
| Kaczorowska, M | 1 |
| Depasse, F | 1 |
| Rajna, P | 1 |
| Macleod, S | 1 |
| Appleton, RE | 3 |
| Conway, M | 2 |
| Cubbidge, RP | 1 |
| Kjellström, U | 1 |
| Lövestam-Adrian, M | 1 |
| Andréasson, S | 1 |
| Ponjavic, V | 1 |
| Ticus, I | 1 |
| Hugonencq, C | 1 |
| Hwang, H | 1 |
| Kim, KJ | 1 |
| D'Argenzio, L | 1 |
| Wang, QP | 1 |
| Jammoul, F | 1 |
| Duboc, A | 1 |
| Gong, J | 1 |
| Simonutti, M | 1 |
| Dubus, E | 1 |
| Craft, CM | 1 |
| Ye, W | 1 |
| Sahel, JA | 1 |
| Picaud, S | 1 |
| Camposano, SE | 1 |
| Major, P | 1 |
| Halpern, E | 1 |
| Rimmer, EM | 1 |
| Brandt, NJ | 1 |
| Christensen, E | 1 |
| Schechter, PJ | 2 |
| Hanke, NF | 1 |
| Grove, J | 1 |
| Huebert, N | 2 |
| Sjoerdsma, A | 1 |
| Gram, L | 12 |
| Lyon, BB | 1 |
| Dam, M | 7 |
| Despland, PA | 2 |
| Mattson, RH | 9 |
| Petroff, OA | 7 |
| Rothman, D | 2 |
| Behar, K | 2 |
| Schmidt, D | 2 |
| Russ, W | 2 |
| Aikiä, M | 2 |
| Saukkonen, AM | 1 |
| Mervaala, E | 4 |
| Riekkinen, PJ | 8 |
| Kilpatrick, C | 1 |
| Pacifici, R | 1 |
| Zuccaro, P | 1 |
| Iannetti, P | 1 |
| Raucci, U | 1 |
| Imperato, C | 1 |
| Rothman, DL | 6 |
| Behar, KL | 4 |
| de Krom, MC | 1 |
| Verduin, N | 1 |
| Visser, E | 1 |
| Kleijer, M | 1 |
| Scholtes, F | 1 |
| De Groen, JH | 1 |
| Krämer, G | 3 |
| Lahat, E | 4 |
| Pimentel, J | 1 |
| Pinto, F | 1 |
| O'Neill, BA | 1 |
| Bloom, DS | 1 |
| Herranz, JL | 4 |
| Arteaga, R | 4 |
| Armijo, JA | 5 |
| Dodrill, CB | 2 |
| Arnett, JL | 2 |
| Sommerville, KW | 2 |
| Sussman, NM | 3 |
| Devinsky, O | 1 |
| Vazquez, B | 1 |
| Luciano, D | 1 |
| Vogt, H | 1 |
| Patsalos, PN | 1 |
| Di Bartolo, RM | 1 |
| Di Marco, V | 1 |
| Mostardini, R | 1 |
| van der Zwan, A | 2 |
| Buchanan, N | 2 |
| Jackson, GD | 1 |
| Grünewald, RA | 1 |
| Connelly, A | 2 |
| Lammers, MW | 1 |
| Wijsman, DJ | 1 |
| Hekster, YA | 1 |
| Keyser, A | 1 |
| Renier, WO | 1 |
| Meinardi, H | 2 |
| van Lier, H | 1 |
| Nakken, KO | 1 |
| Henriksen, O | 1 |
| Williams, A | 1 |
| Goldsmith, R | 1 |
| Coakley, J | 1 |
| Srinivasan, J | 1 |
| Wolf, P | 3 |
| Mumford, JP | 11 |
| Cannon, DJ | 2 |
| Petroff, O | 1 |
| Halonen, T | 5 |
| Pitkänen, A | 11 |
| Byers, VL | 1 |
| Cocito, L | 1 |
| Maffini, M | 1 |
| Loeb, C | 1 |
| Martin, PJ | 1 |
| Millac, PA | 1 |
| Rogers, D | 1 |
| Bird, J | 1 |
| Eames, P | 1 |
| Leppik, IE | 3 |
| Lhoir, A | 1 |
| Mazurkiewicz, M | 1 |
| Sirviö, J | 2 |
| Riekkinen, P | 7 |
| Graves, NM | 1 |
| Slater, JD | 1 |
| Gillham, RA | 1 |
| Blacklaw, J | 1 |
| McKee, PJ | 1 |
| Herranz Fernández, JL | 1 |
| Preece, MA | 1 |
| Sewell, IJ | 1 |
| Taylor, JA | 1 |
| Green, A | 1 |
| Schramm, TM | 1 |
| McKinnon, GE | 1 |
| Eadie, MJ | 1 |
| Heinzl, S | 1 |
| Ylinen, A | 7 |
| Matilainen, R | 6 |
| Luukkainen, R | 1 |
| Seppänen, R | 1 |
| Ruutiainen, T | 5 |
| Fassbender, CP | 1 |
| Gramer, M | 1 |
| Hörstermann, D | 1 |
| Zahner, B | 2 |
| Stefan, H | 4 |
| Wong, IC | 3 |
| Uldall, P | 3 |
| Alving, J | 3 |
| Høgenhaven, H | 1 |
| Cánovas Martínez, A | 1 |
| Ordovás Baines, JP | 1 |
| Beltrán Marqués, M | 1 |
| Escrivá Aparisi, A | 1 |
| Delgado Cordón, F | 1 |
| Legido, A | 1 |
| Monaco, F | 1 |
| Iivanainen, M | 1 |
| Gaily, E | 1 |
| Loiseau, P | 1 |
| Macdonald, RL | 1 |
| Kelly, KM | 1 |
| Rogvi-Hansen, B | 1 |
| Ryan, MF | 1 |
| Samy, A | 1 |
| Young, J | 1 |
| McDonnell, GV | 1 |
| Morrow, JI | 1 |
| Kellermann, K | 1 |
| Soditt, V | 1 |
| Rambeck, B | 1 |
| Klinge, O | 1 |
| Bourgeois, BF | 3 |
| Ferrie, CD | 1 |
| Robinson, RO | 1 |
| Panayiotopoulos, CP | 2 |
| Provinciali, L | 1 |
| Bartolini, M | 1 |
| Mari, F | 1 |
| Del Pesce, M | 1 |
| Ceravolo, MG | 1 |
| Jackson, D | 1 |
| Duthie, T | 1 |
| Kadir, ZA | 2 |
| Walker, MC | 1 |
| Li, LM | 1 |
| Meldrum, BS | 1 |
| Guberman, A | 1 |
| Schapel, G | 1 |
| Chadwick, D | 1 |
| Collins, TL | 1 |
| Grippo, J | 1 |
| López-Valdés, E | 1 |
| Hernández-Laín, A | 1 |
| Simón, R | 1 |
| Porta, J | 1 |
| Mateos, F | 1 |
| Mercadé Cerdá, JM | 1 |
| Wilson, EA | 2 |
| Mauguière, F | 1 |
| Chauvel, P | 3 |
| Dewailly, J | 1 |
| Dousse, N | 1 |
| Shorvon, S | 1 |
| Neufeld, MY | 1 |
| Korczyn, AD | 1 |
| Padró, L | 1 |
| Arbizu, T | 1 |
| Rovira, R | 1 |
| Bonanni, E | 1 |
| Massetani, R | 1 |
| Galli, R | 1 |
| Gneri, C | 1 |
| Petri, M | 1 |
| Iudice, A | 3 |
| Murri, L | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Chapman, DP | 1 |
| Giles, WH | 1 |
| Lortie, A | 1 |
| Dumas, C | 1 |
| Lambert, MV | 1 |
| Bird, JM | 1 |
| Wyler, AR | 1 |
| Vossler, DG | 1 |
| Dalby, NO | 1 |
| Nielsen, EB | 1 |
| Cuadrado, A | 1 |
| Bravo, J | 1 |
| Prichard, JW | 1 |
| Coppola, G | 1 |
| Terraciano, AM | 1 |
| Pascotto, A | 1 |
| Kayemba Kay'S, S | 1 |
| Beust, M | 1 |
| Aboulghit, H | 1 |
| Voisin, M | 1 |
| Mourtada, A | 1 |
| Van Paesschen, W | 1 |
| Bazil, CW | 1 |
| Pedley, TA | 1 |
| Schapel, GJ | 1 |
| Wallace, SJ | 2 |
| Gordon, GS | 1 |
| Hutton, JL | 1 |
| Lücke, A | 2 |
| Musshoff, U | 2 |
| Köhling, R | 2 |
| Osterfeld, M | 1 |
| Mayer, T | 1 |
| Schütte, W | 1 |
| Speckmann, EJ | 1 |
| Schulze, A | 1 |
| Mayatepek, E | 1 |
| Frank, S | 1 |
| Marescau, B | 1 |
| De Deyn, PP | 1 |
| Bachert, P | 1 |
| Bélanger, S | 1 |
| Coulombe, G | 1 |
| Carmant, L | 1 |
| Garaizar, C | 1 |
| Pérez-García, J | 1 |
| Gil-Antón, J | 1 |
| Prats, JM | 1 |
| Thijs, RD | 1 |
| Kerr, MP | 1 |
| Kloster, R | 1 |
| Børresen, HC | 1 |
| Hoff-Olsen, P | 1 |
| Kuenzle, C | 1 |
| Steinlin, M | 1 |
| Wohlrab, G | 1 |
| Boltshauser, E | 1 |
| Vermeij, TA | 1 |
| Edelbroek, PM | 2 |
| Feely, M | 1 |
| Blankenhorn, V | 1 |
| Thümler, R | 1 |
| Veggiotti, P | 1 |
| De Agostini, G | 1 |
| Muzio, C | 1 |
| Termine, C | 1 |
| Baldi, PL | 1 |
| Ferrari Ginevra, O | 1 |
| Lanzi, G | 1 |
| Reinharz, D | 1 |
| Kennedy, W | 1 |
| Contandriopoulos, AP | 1 |
| Tessier, G | 1 |
| Champagne, F | 1 |
| Erdal, J | 1 |
| Novotny, EJ | 1 |
| Hyder, F | 1 |
| Shevell, M | 1 |
| Vanhatalo, S | 3 |
| Pääkkönen, L | 1 |
| Nousiainen, I | 5 |
| Carvill, S | 1 |
| Clarke, D | 1 |
| Cassidy, G | 1 |
| Salmenperä, T | 1 |
| Fisher, R | 1 |
| French, J | 1 |
| Storici, P | 1 |
| Capitani, G | 1 |
| De Biase, D | 1 |
| Moser, M | 1 |
| John, RA | 1 |
| Jansonius, JN | 1 |
| Schirmer, T | 1 |
| Bernatik, J | 1 |
| Knorr, J | 1 |
| Ben-Zeev, B | 1 |
| Zlotnik, J | 1 |
| Sela, BA | 1 |
| Valdizán, EM | 2 |
| García, AP | 1 |
| Fenwick, PB | 1 |
| Mawer, GE | 2 |
| Elger, CE | 1 |
| Fernández, G | 1 |
| Appleton, R | 1 |
| Paillard, C | 1 |
| Vanhulle, C | 1 |
| Devaux, AM | 1 |
| Ensel, P | 1 |
| Monroc-Morval, M | 1 |
| Blanc, T | 1 |
| Eke, T | 1 |
| Degg, C | 1 |
| Dimova, PS | 1 |
| Butler, E | 1 |
| Thompson, GG | 1 |
| Martinez, C | 2 |
| Reinshagen, G | 1 |
| Datta, PK | 1 |
| Crawford, PM | 2 |
| Cohen, JA | 1 |
| Fisher, RS | 1 |
| Peyster, RG | 1 |
| Sze, G | 1 |
| Zubcević, S | 1 |
| Gavranović, M | 1 |
| Catibusić, F | 1 |
| Uzicanin, S | 1 |
| Buljina, A | 1 |
| Jedrzejczak, J | 2 |
| Dławichowska, E | 1 |
| Owczarek, K | 2 |
| Majkowski, J | 1 |
| Maciejek, Z | 1 |
| Niezgodzińska-Maciejek, A | 1 |
| Kozik, A | 1 |
| Ujma-Czapska, B | 1 |
| Grotowska, M | 1 |
| Manuchehri, K | 1 |
| Goodman, S | 1 |
| Siviter, L | 1 |
| Nightingale, S | 1 |
| Mäntyjärvi, M | 2 |
| George, S | 1 |
| Gill, L | 1 |
| Braithwaite, RA | 1 |
| Lukasiuk, K | 1 |
| Vajda, FJ | 1 |
| Comaish, IF | 2 |
| Gorman, C | 2 |
| Galloway, NR | 2 |
| Engel, D | 1 |
| Endermann, U | 1 |
| Frahm, C | 1 |
| Heinemann, U | 1 |
| Draguhn, A | 1 |
| Rüsch, N | 1 |
| Betts, T | 1 |
| Krakow, K | 1 |
| Polizzi, G | 1 |
| Riordan-Eva, P | 1 |
| Holder, G | 1 |
| MacLeod, WN | 1 |
| Fish, DR | 1 |
| Medura, M | 1 |
| Paul, SR | 2 |
| Shahar, E | 2 |
| Casas-Fernández, C | 1 |
| Speckmann, E | 1 |
| Tuxhorn, I | 1 |
| Pauuek, HW | 1 |
| Oppel, F | 1 |
| Rietbrock, S | 1 |
| Russell-Eggitt, IM | 1 |
| Mackey, DA | 1 |
| Taylor, DS | 1 |
| Timms, C | 1 |
| Walker, JW | 1 |
| Engelsman, M | 2 |
| van Veelen, CW | 1 |
| Stilma, JS | 2 |
| Betts, TA | 1 |
| Barber, C | 2 |
| Barnes, PM | 1 |
| Zgorzalewicz, M | 1 |
| Galas-Zgorzalewicz, B | 1 |
| Harden, CL | 1 |
| Foletti, GB | 1 |
| Singhi, PD | 1 |
| García Pastor, A | 1 |
| García-Zarza, E | 1 |
| Peraita Adrados, R | 1 |
| Luchetti, A | 1 |
| Amadi, A | 1 |
| Gobbi, G | 1 |
| Mueller, SG | 1 |
| Weber, OM | 1 |
| Duc, CO | 1 |
| Weber, B | 1 |
| Meier, D | 1 |
| Boesiger, P | 1 |
| Wieser, HG | 1 |
| Prasad, AN | 1 |
| Penney, S | 1 |
| Buckley, DJ | 1 |
| Aliev, NA | 1 |
| Verduin, WM | 1 |
| Segers, JP | 1 |
| Berendschot, TT | 1 |
| Nissinen, J | 1 |
| Kluger, G | 1 |
| Berz, K | 1 |
| Holthausen, H | 1 |
| Aldenkamp, AP | 1 |
| Medura, MT | 1 |
| Miller, TA | 1 |
| Humbertclaude, V | 1 |
| Rivier, F | 1 |
| Roubertie, A | 1 |
| Echenne, B | 1 |
| Bellet, H | 1 |
| Vallat, C | 1 |
| Morin, D | 1 |
| Stuchlík, A | 1 |
| Kubová, H | 1 |
| Beran, RG | 2 |
| Koul, R | 1 |
| Chacko, A | 1 |
| Ganesh, A | 1 |
| Bulusu, S | 1 |
| Al Riyami, K | 1 |
| Juhász, C | 1 |
| Muzik, O | 1 |
| Chugani, DC | 1 |
| Shen, C | 1 |
| Janisse, J | 1 |
| Chugani, HT | 1 |
| Hisama, FM | 1 |
| Lee, HH | 1 |
| Felice, K | 1 |
| Alen, R | 2 |
| Rantala, H | 2 |
| Aine, MR | 2 |
| Mustonen, K | 2 |
| Lewis, H | 1 |
| Beghi, E | 1 |
| Annegers, JF | 1 |
| Shalev, R | 1 |
| Spencer, EL | 1 |
| Bohn, RL | 1 |
| Logan, WJ | 1 |
| Smith, K | 1 |
| Buncic, JR | 1 |
| Panton, CM | 1 |
| Abdolell, M | 1 |
| Besch, D | 1 |
| Kurtenbach, A | 1 |
| Apfelstedt-Sylla, E | 1 |
| Sadowski, B | 1 |
| Dennig, D | 1 |
| Asenbauer, C | 1 |
| Zrenner, E | 1 |
| Jensen, H | 1 |
| Sjö, O | 1 |
| van der Torren, K | 2 |
| Graniewski-Wijnands, HS | 2 |
| Polak, BC | 1 |
| Brimlow, GM | 1 |
| Orr, GM | 1 |
| Cui, X | 1 |
| Eriksson, K | 1 |
| Vainionpää, L | 1 |
| Aärimaa, T | 1 |
| Byring, R | 1 |
| Hirvasniemi, A | 1 |
| Nuutila, A | 1 |
| Walden, T | 1 |
| Ritanen-Mohammed, UM | 1 |
| Karttunen-Lewandowski, P | 1 |
| Pohjola, LM | 1 |
| Kaksonen, S | 1 |
| Jurvelin, P | 1 |
| Granström, ML | 1 |
| Gale, K | 2 |
| Hammond, EJ | 5 |
| Ballinger, WE | 1 |
| Lu, L | 1 |
| Wilder, BJ | 6 |
| Uthman, BM | 1 |
| Reid, SA | 1 |
| Rey, E | 2 |
| Pons, G | 2 |
| Olive, G | 2 |
| Tartara, A | 3 |
| Manni, R | 3 |
| Galimberti, CA | 3 |
| Morini, R | 1 |
| Schroeder, CE | 1 |
| Gibson, JP | 1 |
| Yarrington, J | 1 |
| Heydorn, WE | 1 |
| Arezzo, JC | 1 |
| Sabers, A | 2 |
| Reynolds, EH | 4 |
| Jongsma, MJ | 1 |
| Laan, LA | 1 |
| van Emde Boas, W | 1 |
| Grant, SM | 1 |
| Heel, RC | 1 |
| Lewis, PJ | 2 |
| Hart, YM | 2 |
| Shorvon, SD | 3 |
| Lahtinen, H | 1 |
| Ronkainen, A | 1 |
| Butler, WH | 1 |
| Mumford, J | 3 |
| Luna, D | 1 |
| Pajot, N | 1 |
| Beaumont, D | 7 |
| Mondragon, S | 1 |
| Beck, S | 1 |
| Farr, IN | 2 |
| Valdizan, E | 1 |
| Partanen, J | 2 |
| Sivenius, J | 3 |
| Saksa, M | 1 |
| O'Donohoe, NV | 1 |
| Krutschmann, I | 1 |
| Duncan, R | 1 |
| Robinson, MK | 1 |
| Oxley, R | 1 |
| Speciale, J | 1 |
| Dayrell-Hart, B | 1 |
| Steinberg, SA | 1 |
| Richard, MO | 1 |
| Vauzelle, F | 1 |
| D'Athis, P | 1 |
| Trevisol-Bittencourt, PC | 1 |
| Ring, HA | 1 |
| Heller, AJ | 1 |
| Persson, LI | 1 |
| Haegele, KD | 1 |
| Hardenberg, J | 1 |
| Dahlgren, L | 1 |
| Mikkelsen, M | 1 |
| Porter, RJ | 1 |
| Browne, TR | 1 |
| Penry, JK | 1 |
| Smith, DB | 1 |
| Miketta, RM | 1 |
| Sherry, KM | 1 |
| Szabo, GK | 1 |
| Livingston, JH | 1 |
| Aicardi, J | 1 |
| Remy, C | 1 |
| Cosi, V | 1 |
| Callieco, R | 1 |
| Liegeois-Chauvel, C | 2 |
| Marquis, P | 2 |
| Gisselbrecht, D | 2 |
| Pantieri, R | 2 |
| Lehtinen, M | 1 |
| Ambrosetto, G | 1 |
| Salvi, F | 1 |
| Persson, L | 1 |
| Rangel, RJ | 1 |
| Holonen, T | 1 |
| Ring, H | 1 |
| Heller, A | 1 |
| Rimmer, E | 1 |
| Kongola, G | 1 |
| Sarlund, H | 1 |
| Pedersen, B | 1 |
| Højgaard, K | 1 |
| Frey, HH | 1 |
| Pedersen, SA | 1 |
| Klosterskov, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial[NCT03689114] | Phase 4 | 374 participants (Anticipated) | Interventional | 2020-01-07 | Not yet recruiting | ||
| Decreasing Parental Stress and Costs While Improving Overall Satisfaction of Caregivers of Infants With Infantile Spasms on ACTH Therapy Utilizing Innovative Telemedicine Technology: A Randomized Study[NCT04086992] | 40 participants (Anticipated) | Interventional | 2019-10-10 | Recruiting | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen[NCT00626340] | Phase 4 | 18 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism[NCT00001489] | 20 participants | Observational | 1994-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone
| Intervention | () |
|---|---|
| All Participants | 0 |
125 reviews available for vigabatrin and Aura
| Article | Year |
|---|---|
Vigabatrin - new data on indications and safety in paediatric epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Spasms, Infantile; Tuberous Sclerosis; Vigabatrin | 2021 |
Precision Therapy for Epilepsy Related to Brain Malformations.
Topics: Animals; Anticonvulsants; Epilepsy; Everolimus; Humans; Malformations of Cortical Development; MTOR | 2021 |
Sex differences in side effects of antiseizure medications in pediatric patients with epilepsy: A systematic review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Female; Hu | 2022 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve | 2022 |
Overview of therapeutic options for epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Prognosis; Seizures; Spasms, | 2022 |
Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis.
Topics: Anticonvulsants; Child; Early Diagnosis; Epilepsy; Humans; Infant; Infant, Newborn; Seizures; Tubero | 2022 |
Biochemical mechanisms in pathogenesis of infantile epileptic spasm syndrome.
Topics: Anticonvulsants; Epilepsy; Glucocorticoids; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2023 |
Recent advances in pharmacotherapy for epilepsy.
Topics: Adult; Anticonvulsants; Child; Epilepsies, Myoclonic; Epilepsies, Partial; Epilepsy; Fenfluramine; H | 2023 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef | 2020 |
Three different scenarios for epileptic spasms.
Topics: Child; Electroencephalography; Epilepsy; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2020 |
Reduction of retinal nerve fiber layer thickness in vigabatrin-exposed patients: A meta-analysis.
Topics: Epilepsy; Female; Humans; Male; Nerve Fibers; Retina; Retinal Ganglion Cells; Tomography, Optical Co | 2017 |
Weight change, genetics and antiepileptic drugs.
Topics: Animals; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Huma | 2014 |
Pharmacology aspects during transition and at transfer in patients with epilepsy.
Topics: Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Transition to Adult Care; Treatment Out | 2014 |
Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Topics: Animals; Autism Spectrum Disorder; Brain; Epilepsy; GABA Agents; Humans; Neurons; TOR Serine-Threoni | 2015 |
Vigabatrin versus carbamazepine monotherapy for epilepsy.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Randomized Controlled Trials as Topic; Risk Assess | 2015 |
Stiripentol and vigabatrin current roles in the treatment of epilepsy.
Topics: Anticonvulsants; Combined Modality Therapy; Dioxolanes; Epilepsy; Humans; Infant; Treatment Outcome; | 2016 |
Treatment issues for children with epilepsy transitioning to adult care.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Cannabidiol; Child; Congresses as Topic; Diet, Keto | 2017 |
Genetic basis for idiosyncratic reactions to antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Epile | 2009 |
New pharmacotherapies for pediatric seizures.
Topics: Adolescent; Amines; Animals; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecar | 2004 |
Behavioral and cognitive effects of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Antidepressive Agents; Behavior; Cognition; Cognition Disorders; Cyclohexan | 2010 |
Vigabatrin for infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Clinical Trials as Topic; Electroenc | 2011 |
Epilepsy (partial).
Topics: Anticonvulsants; Clinical Trials as Topic; Cost-Benefit Analysis; Epilepsies, Partial; Epilepsy; Hum | 2010 |
Epilepsy (partial).
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Humans; Phenytoin; Vigabatrin | 2011 |
Vigabatrin versus carbamazepine monotherapy for epilepsy.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Randomized Controlled Trials as Topic; Risk Assess | 2012 |
Vigabatrin-associated retinal damage: potential biochemical mechanisms.
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Retinal Diseases; Taurine; Vigabatrin | 2012 |
ACS chemical neuroscience molecule spotlight on Sabril.
Topics: 4-Aminobutyrate Transaminase; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Enzyme | 2010 |
Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance.
Topics: 4-Aminobutyrate Transaminase; Electroretinography; Enzyme Inhibitors; Epilepsy; Eye; Humans; Regiona | 2002 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2003 |
[Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2003 |
Adverse effects of new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Felbamate; Humans; Phenylcarbamat | 2004 |
Pharmacologic treatment of the catastrophic epilepsies.
Topics: Anticonvulsants; Child, Preschool; Epilepsies, Myoclonic; Epilepsy; Fructose; Humans; Infant; Isoxaz | 2004 |
Managing epilepsy in tuberous sclerosis complex.
Topics: Anticonvulsants; Child; Cognition Disorders; Diet Therapy; Electroencephalography; Epilepsy; Humans; | 2004 |
Current management for epilepsy in tuberous sclerosis complex.
Topics: Animals; Anticonvulsants; Brain Injuries; Cognition Disorders; Epilepsy; Humans; Neurosurgery; Tuber | 2006 |
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor | 2006 |
Vigabatrin.
Topics: Animals; Anticonvulsants; Brain; Clinical Trials as Topic; Epilepsy; Humans; Risk Assessment; Vigaba | 2007 |
[Epilepsy and Sabril].
Topics: Adult; Algorithms; Animals; Anticonvulsants; Child; Epilepsy; Humans; Optic Nerve Diseases; Retinal | 2007 |
[Effects of antiepileptic drugs on mood of people with epilepsy].
Topics: Affect; Anticonvulsants; Antidepressive Agents; Carbamazepine; Depressive Disorder; Epilepsy; Fructo | 2007 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?].
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxyli | 1995 |
Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy.
Topics: Anticonvulsants; Brain; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; | 1995 |
Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin.
Topics: Anticonvulsants; Brain; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Epil | 1995 |
Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Epilepsy | 1995 |
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju | 1994 |
[Vigabatrin in the treatment of pediatric epileptic syndrome].
Topics: Anticonvulsants; Child; Epilepsy; gamma-Aminobutyric Acid; Humans; Syndrome; Vigabatrin | 1995 |
[New antiepileptic medications].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; | 1995 |
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1995 |
New antiepileptic drugs--an explosion of activity.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug Interactions; Dr | 1995 |
[New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
Topics: Anticonvulsants; Epilepsy; Felbamate; gamma-Aminobutyric Acid; Humans; Lamotrigine; Phenylcarbamates | 1994 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
[Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, | 1995 |
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane | 1994 |
New anti-epileptic drugs in the 1990s.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1994 |
A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Brain; Child; Clinical Trials as Topic; Doub | 1994 |
Vigabatrin.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Epilepsy; ga | 1994 |
Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Brain Chemistry; Clinical Trials as Topic; D | 1994 |
Antiepileptic drugs in development: prospects for the near future.
Topics: Acetates; Adult; Amines; Aminocaproates; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohe | 1994 |
Advances in pharmacotherapy: recent developments in the treatment of epilepsy.
Topics: Acetates; Amines; Aminocaproates; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Aci | 1993 |
The role of vigabatrin in the management of infantile epileptic syndromes.
Topics: Aminocaproates; Anticonvulsants; Child, Preschool; Epilepsies, Partial; Epilepsy; Humans; Infant; Sp | 1993 |
Antiepileptic drugs in clinical development.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Brain; Clinical Trials as Topic; Cyclohexanecarbo | 1993 |
[Contribution of new drugs to the better control of epilepsy].
Topics: Aminocaproates; Anticonvulsants; Child; Delayed-Action Preparations; Epilepsy; Felbamate; Humans; Ph | 1993 |
Vigabatrin-associated reversible acute psychosis in a child.
Topics: 4-Aminobutyrate Transaminase; Acute Disease; Anticonvulsants; Child; Clinical Trials as Topic; Enzym | 1995 |
Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Clinical Trials as Topic; | 1996 |
Utilization of new antiepileptic drugs in children.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Child, Pres | 1996 |
[Advances in the diagnostic and treatment of infantile epilepsy].
Topics: Acetates; Amines; Anticonvulsants; Brain; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Elec | 1996 |
Cognitive effects of vigabatrin: a review.
Topics: Anticonvulsants; Cognition; Epilepsy; gamma-Aminobutyric Acid; Humans; Psychomotor Performance; Viga | 1996 |
[Current anti-epilepsy drugs].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 1995 |
Antiepileptic drug mechanisms of action.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Barbiturates; Benzodiazepines; Calciu | 1995 |
Vigabatrin.
Topics: Animals; Anticonvulsants; Biological Availability; Child; Clinical Trials as Topic; Disease Models, | 1995 |
Adverse effects of established and new antiepileptic drugs: an attempted comparison.
Topics: Animals; Anticonvulsants; Carbamazepine; Epilepsy; gamma-Aminobutyric Acid; Gastrointestinal Disease | 1995 |
Important pharmacokinetic properties of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Biopharmaceutics; Carbamazepine; Cyclohe | 1995 |
Psychotic and severe behavioural reactions with vigabatrin: a review.
Topics: Adult; Anticonvulsants; Child; Contraindications; Dose-Response Relationship, Drug; Epilepsy; Epilep | 1996 |
New antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cross-Over Studies; Cyclohexaneca | 1996 |
Pharmacokinetics of new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Cyclohexanecarboxylic Aci | 1996 |
Update on the mechanism of action of antiepileptic drugs.
Topics: 4-Aminobutyrate Transaminase; Acetamides; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecar | 1996 |
The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.
Topics: Acetates; Amines; Anticonvulsants; Cerebral Palsy; Cyclohexanecarboxylic Acids; Disabled Persons; Dr | 1996 |
[Advantages and disadvantages of new antiepileptic drugs].
Topics: Acetates; Adrenocorticotropic Hormone; Amines; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; | 1996 |
[Treatment of the epilepsy: new drugs].
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz | 1996 |
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
New antiepileptic drugs.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; F | 1996 |
[Antiepileptic drugs: mechanism of action].
Topics: Anticonvulsants; Barbiturates; Carbamazepine; Epilepsy; GABA Antagonists; gamma-Aminobutyric Acid; H | 1996 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; | 1996 |
Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitoring; | 1997 |
Overview of the safety of newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Inter | 1997 |
Vigabatrin.
Topics: Animals; Anticonvulsants; Child; Epilepsy; gamma-Aminobutyric Acid; Humans; Vigabatrin | 1997 |
New drugs and vagal stimulation for treatment of epilepsy--the Israeli experience.
Topics: Adult; Antidepressive Agents; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Lamotrigine; Male; | 1996 |
[New antiepileptic drugs].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam | 1997 |
Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.
Topics: Acetates; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epil | 1997 |
Recent advancements in epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
Overview of lamotrigine and the new antiepileptic drugs: the challenge.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1997 |
Advances in the medical treatment of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diazepam; Drug Approv | 1998 |
Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Anticonvulsants; Brain; Brain Chemistry; Cyclohexane | 1998 |
The new antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug | 1997 |
Role of new and established antiepileptic drugs.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsies, Partial; Epilepsy | 1998 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Approval; Epilep | 1998 |
Fortnightly review: drug treatment of epilepsy.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Barbiturates; Benzodiazepines; Clobazam; Clo | 1999 |
New antiepileptic drugs: comparison of key clinical trials.
Topics: Acetates; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; | 1999 |
Options after the first antiepileptic drug has failed.
Topics: Acetates; Amines; Anticonvulsants; Attitude to Health; Carbamazepine; Clinical Trials as Topic; Cycl | 1999 |
Monostars: an aid to choosing an antiepileptic drug as monotherapy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Administration S | 1999 |
Use of new antiepileptic drugs in the treatment of childhood epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanec | 1999 |
Managing pediatric epilepsy syndromes with new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose | 1999 |
The potential for vigabatrin-induced intramyelinic edema in humans.
Topics: Animals; Anticonvulsants; Brain; Brain Diseases; Clinical Trials as Topic; Dogs; Edema; Epilepsy; Ev | 2000 |
[GABA-ergic system and antiepileptic drugs].
Topics: Acetates; Amines; Anticonvulsants; Binding, Competitive; Calcium Channels; Chloride Channels; Cycloh | 2000 |
New antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2000 |
[Current data on vigabatrin].
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Visual Fields | 2000 |
[Vigabatrin: balancing effectiveness vs. (irreversible) visual field loss as a side effect].
Topics: 4-Aminobutyrate Transaminase; Anticonvulsants; Contraindications; Enzyme Inhibitors; Epilepsy; Human | 2000 |
Therapeutic safety monitoring: what to look for and when to look for it.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Monitoring; Epil | 2000 |
Newer antiepileptic drugs and non surgical approaches in epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Immunoglobulins; Lamotrigine; Triazines; Vigabatrin | 2000 |
[Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy] .
Topics: Acute Disease; Aged; Anticonvulsants; Brain Diseases, Metabolic; Cerebral Infarction; Disease Suscep | 2000 |
A risk-benefit assessment of treatments for infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Epilepsy; Humans; Immunoglobulins; Infant; Pyridoxine; | 2001 |
Vigabatrin.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Anticonvulsants; Child; Epilepsy; Humans; Vigabatr | 2001 |
GABA and epilepsy: basic concepts from preclinical research.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Muscimol | 1992 |
Vigabatrin. Clinical pharmacokinetics.
Topics: Administration, Oral; Adult; Aminocaproates; Anticonvulsants; Biological Availability; Child; Epilep | 1992 |
Gamma-vinyl GABA (vigabatrin): clinical experience in adult and adolescent patients with intractable epilepsy.
Topics: Adolescent; Adult; Age Factors; Aminocaproates; Anticonvulsants; Chronic Disease; Epilepsies, Partia | 1992 |
Pharmacology of vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Animals; Anticonvulsants; Drug Interactions; Epilepsy; | 1992 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
Vigabatrin.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain; Drugs, Investigational; Electroencephalography; Epi | 1991 |
Vigabatrin in refractory epilepsy in adults and its application in children.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epileps | 1991 |
Vigabatrin: a new antiepileptic medication.
Topics: 4-Aminobutyrate Transaminase; Adult; Aminocaproates; Animals; Anticonvulsants; Brain; Child; Epileps | 1991 |
Pharmacology and clinical pharmacology of vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adult; Aminocaproates; Animals; Anticonvulsants; Brain; Child; Drug In | 1991 |
Vigabatrin.
Topics: Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Vigabatrin | 1990 |
Vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Animals; Anticonvulsants; Brain Edema; Epilepsy; Human | 1989 |
Gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Behavior, Animal; beta-Alanine; | 1985 |
Clinical benefits of vigabatrin.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Midd | 1988 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
69 trials available for vigabatrin and Aura
| Article | Year |
|---|---|
Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial.
Topics: Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Follow-Up | 2019 |
Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?
Topics: Anticonvulsants; Autism Spectrum Disorder; Child, Preschool; Developmental Disabilities; Epilepsy; F | 2020 |
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Electroencephalography; Epilepsy; Female; Humans; Infant; | 2021 |
Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes.
Topics: Anticonvulsants; Developmental Disabilities; Early Diagnosis; Electroencephalography; Epilepsy; Fema | 2021 |
Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow.
Topics: Adult; Analysis of Variance; Anticonvulsants; Blood Pressure; Cerebrovascular Circulation; Cohort St | 2003 |
A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.
Topics: Adult; Aged; Anticonvulsants; Cross-Sectional Studies; Electroretinography; Epilepsy; Female; Humans | 2003 |
Responsiveness of the quality of life in epilepsy inventory (QOLIE-89) in an antiepileptic drug trial.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Placebos; Psychometrics; Qualit | 2003 |
[Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Humans; Middle Aged; Predictive Value of Tests; | 2003 |
Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Autistic Disorder; Cognition Disorders; Electroencepha | 2003 |
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Topics: Adaptation, Psychological; Anti-Inflammatory Agents; Anticonvulsants; Child Development; Cosyntropin | 2005 |
Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aminocaproates; Clinical Trials as Topic; Double-Bl | 1984 |
Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.
Topics: Adult; Aminocaproates; Central Nervous System; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Ma | 1984 |
Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy | 1983 |
Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Male; Midd | 1995 |
Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy.
Topics: Adolescent; Adult; Affect; Anticonvulsants; Cognition; Dose-Response Relationship, Drug; Double-Blin | 1995 |
Vigabatrin treatment in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy | 1994 |
[Vigabatrin: results with a new antiepileptic agents in 57 patients in a general neurological practice].
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Dru | 1994 |
Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Brain; Double-Blind Method; Electroencephalography; Epilepsy; Fe | 1994 |
Vigabatrin in chronic epilepsy: a 7-year follow-up study of responder patients.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Drug Therapy, Combination; Electroencephalograph | 1993 |
Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy.
Topics: Adaptation, Psychological; Adult; Affect; Aminocaproates; Anticonvulsants; Cognition; Double-Blind M | 1993 |
Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Analysis of Variance; Anticonvulsants; Cognition; Double-Blind Me | 1993 |
Retrospective study of vigabatrin and psychiatric behavioural disturbances.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; gamma-Aminobut | 1995 |
Vigabatrin causes profound reduction in serum alanine transaminase activity.
Topics: Alanine Transaminase; Anticonvulsants; Child; Enzyme Inhibitors; Epilepsy; gamma-Aminobutyric Acid; | 1996 |
Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cognition; Epilepsy; Female; gamma-Aminobutyric Acid; Huma | 1996 |
Vigabatrin withdrawal randomized study in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Epilepsies, Partial; Epil | 1996 |
No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Administration Schedule; Epilepsy; Evoked Potentials, | 1997 |
A quantitative study of daytime sleepiness induced by carbamazepine and add-on vigabatrin in epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; gamm | 1997 |
Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combinat | 1997 |
A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements.
Topics: Adolescent; Adult; Anticonvulsants; Brain; Brain Mapping; Carbamazepine; Cerebellum; Epilepsy; Femal | 1998 |
[Therapeutic failure, treatment and non-treatment of childhood epilepsy].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Electroencephalography; Epileps | 1998 |
Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexanecarbox | 1998 |
Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Epilepsy; Follow-Up Studies; | 1998 |
Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 1999 |
Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study.
Topics: Adolescent; Adult; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Drug Administratio | 1999 |
Changes in plasma GABA concentration during vigabatrin treatment of epilepsy: a prospective study.
Topics: Adult; Anticonvulsants; Chromatography, High Pressure Liquid; Epilepsy; Female; gamma-Aminobutyric A | 1999 |
[Visual field defects due to antiepileptic drugs].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dr | 1999 |
Aminoaciduria resulting from vigabatrin administration in children with epilepsy.
Topics: Adolescent; Amino Acids; Aminoisobutyric Acids; Anticonvulsants; beta-Alanine; Child; Child, Prescho | 1999 |
Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Drug Therapy, Combination; Epilepsy; | 2000 |
Quality of life measures in epilepsy: how well can they detect change over time?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2000 |
Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Color Perception; Color Perception Tests; Color Vision | 2000 |
Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics.
Topics: Adolescent; Adult; Anticonvulsants; Brain; Brain Chemistry; Carnosine; Creatine; Epilepsy; Epilepsy, | 2001 |
Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
Topics: Adult; Aged; Anticonvulsants; Color Vision Defects; Drug Administration Schedule; Epilepsy; Female; | 2001 |
Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Electroretinography; Epilepsy; Evo | 2002 |
The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.
Topics: Adult; Anticonvulsants; Control Groups; Electrooculography; Electroretinography; Epilepsy; Female; H | 2002 |
Seizure reduction and quality of life improvements in people with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Attitude to Health; Carbamazepine; Drug Therapy, Combinati | 2002 |
Coadministration of vigabatrin and valproate in children with refractory epilepsy.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Aminocaproates; Anticonvulsants; Blood Platelets; Child; D | 1992 |
Pharmacology of vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Animals; Anticonvulsants; Drug Interactions; Epilepsy; | 1992 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
Vigabatrin in childhood epilepsy.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
Vigabatrin in pediatric epilepsy--an open study.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
Dose-response study of vigabatrin in children with refractory epilepsy.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy: an interim report.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticonvulsants; Carbamazepine; Electroencephalography; Epi | 1991 |
Clinical evaluation of gamma-vinyl-gamma-aminobutyric acid for control of epilepsy in dogs.
Topics: Aminocaproates; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Male; Vigabatrin | 1991 |
Vigabatrin.
Topics: Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Vigabatrin | 1990 |
Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Drug Therapy, Combination; Electroencephalograph | 1990 |
Vigabatrin: rational treatment for chronic epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Chronic Disease; Double-Blind Method; Drug Admin | 1990 |
Vigabatrin in the treatment of epilepsy: a long-term follow-up study.
Topics: Adult; Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1989 |
Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy.
Topics: Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Drug Resistance; Epi | 1989 |
A multicentre study of vigabatrin for drug-resistant epilepsy.
Topics: Adult; Aged; Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Drug Resistance; Epilepsy; F | 1989 |
Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Drug Resistance; | 1989 |
Effects of vigabatrin on evoked potentials in epileptic patients.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Brain Stem; Child; Epilepsy; Evoked Potentials; | 1989 |
Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Dou | 1987 |
Effects of gamma-vinyl-GABA on the human electroencephalogram.
Topics: Adult; Aminocaproates; Anticonvulsants; Cerebral Cortex; Clinical Trials as Topic; Electroencephalog | 1985 |
Clinical benefits of vigabatrin.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Midd | 1988 |
Efficacy and tolerability with long-term administration of vigabatrin.
Topics: Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Epilepsy; Humans; Ti | 1988 |
Studies on gamma-vinyl-GABA in Kuopio, Finland.
Topics: Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Epilepsy; Evoked Pot | 1988 |
A controlled trial of gamma-vinyl-GABA (vigabatrin) in drug-resistant epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; E | 1988 |
Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aminocaproates; Anticonvulsants; Blood Platelets; E | 1988 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
262 other studies available for vigabatrin and Aura
| Article | Year |
|---|---|
Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase.
Topics: 4-Aminobutyrate Transaminase; Animals; Brain; Drug Design; Enzyme Inhibitors; Epilepsy; gamma-Aminob | 2012 |
OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Kindling, Neu | 2021 |
Status of epileptic spasms: A study of 21 children.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsy; Humans; Infant; Spasm; Spasms, Infantile; | 2022 |
Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex.
Topics: Child; Epilepsy; Female; Humans; Male; Pregnancy; Prenatal Diagnosis; Prognosis; Prospective Studies | 2022 |
Treatment of Infantile Spasm Syndrome: Update from the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society of Neuropediatrics.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Epilepsy; Humans; Infant; Spasms, Infantile; Syndrome; | 2022 |
Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials.
Topics: Anticonvulsants; Cosyntropin; Epilepsy; Humans; Infant; Prednisolone; Randomized Controlled Trials a | 2023 |
Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants.
Topics: Anticonvulsants; Brazil; Child; Consensus; Epilepsy; Humans; Infant; Prednisolone; Recurrence; Spasm | 2023 |
Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years.
Topics: Child, Preschool; Clinical Trials as Topic; Epilepsy; Humans; Infant; Infant, Newborn; Multiomics; P | 2023 |
Felbamate in the treatment of refractory epileptic spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Felbamate; Female; Humans; Infant; M | 2020 |
Are Epileptic Spasms a Seizure Type for the Insular Region?
Topics: Adult; Anticonvulsants; Cerebral Cortex; Child; Corpus Striatum; Electroencephalography; Epilepsy; F | 2020 |
Reliability of Handheld Optical Coherence Tomography in Children Younger Than Three Years of Age Undergoing Vigabatrin Treatment for Childhood Epilepsy.
Topics: Child; Epilepsy; Humans; Infant; Nerve Fibers; Reproducibility of Results; Retinal Ganglion Cells; T | 2020 |
Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Health Care Surveys; Hum | 2021 |
Antiepileptogenesis and disease modification: Clinical and regulatory issues.
Topics: Adult; Anticonvulsants; Brain Injuries, Traumatic; Child; Epilepsy; Humans; National Institute of Ne | 2021 |
Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Nerve Fibers; Retin | 2017 |
Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy.
Topics: Anticonvulsants; Brain; Electroencephalography; Epilepsy; Female; Humans; Infant; Male; Retrospectiv | 2017 |
Epilepsy in 2017: Precision medicine drives epilepsy classification and therapy.
Topics: Anticonvulsants; Cannabinoids; Epilepsy; Humans; Precision Medicine; Vigabatrin | 2018 |
Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex.
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Hu | 2018 |
Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin.
Topics: Anticonvulsants; Child, Preschool; Electroretinography; Epilepsy; Female; Humans; Infant; Male; Phot | 2019 |
Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Retrospective Studi | 2019 |
Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
Topics: Animals; Anticonvulsants; Brain; Diet, Ketogenic; Epilepsy; Female; Mechanistic Target of Rapamycin | 2019 |
Evolution of visual field loss over ten years in individuals taking vigabatrin.
Topics: Adult; Anticonvulsants; Disease Progression; Epilepsy; Female; Humans; Longitudinal Studies; Male; M | 2013 |
Electroretinographic responses in epileptic children treated with vigabatrin.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Electroretinography; Epilepsy; Hum | 2014 |
Progressive vigabatrin-associated visual field loss and the importance of continuing assessment of risks and benefit of epilepsy treatments.
Topics: Anticonvulsants; Epilepsy; Humans; Perceptual Disorders; Vigabatrin; Visual Fields | 2013 |
[Characterisation of the paediatric population of Costa Rica with tuberous sclerosis and a description of the behaviour of the associated epilepsy].
Topics: Anticonvulsants; Autistic Disorder; Brain Diseases; Brain Neoplasms; Child, Preschool; Comorbidity; | 2013 |
Medical management of refractory epilepsy--practical treatment with novel antiepileptic drugs.
Topics: Acetamides; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Humans; Lacosamide; Nitriles; Pyri | 2014 |
Relationship between the area of isopters and Vigabatrin dosage during two years of observation.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Follow-Up Studies; Human | 2014 |
Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms.
Topics: Adult; Body Weight; Child; Child, Preschool; Enzyme Inhibitors; Epilepsy; Female; gamma-Aminobutyric | 2014 |
Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diet, Ketogenic; Epilepsies, Partial; Epilepsy | 2015 |
Unintended Consequences: The Story of PERF.
Topics: Adult; Anticonvulsants; Drug Approval; Epilepsy; Foundations; History, 20th Century; Humans; Infant; | 2015 |
Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; Female; Humans; Kaplan-Meier | 2016 |
Plasma taurine levels are not affected by vigabatrin in pediatric patients.
Topics: Age Factors; Analysis of Variance; Anticonvulsants; Child, Preschool; Cohort Studies; Epilepsy; Fema | 2016 |
Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin.
Topics: Anticonvulsants; Brain; Epilepsy; Follow-Up Studies; Humans; Infant; Infant, Newborn; Linear Models; | 2009 |
Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Retina; Retinal Ganglion Cells; Time Factors; Tomo | 2010 |
Visual fields in young children treated with vigabatrin.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Feasibility Studies; Humans; Infant; Vigabatrin; | 2009 |
Early infantile epileptic encephalopathy with unusual favourable outcome.
Topics: Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Female; Humans; Infant; Male; Pre | 2010 |
Visual impairment at large eccentricity in participants treated by vigabatrin: visual, attentional or recognition deficit?
Topics: Adolescent; Adult; Analysis of Variance; Attention; Cues; Epilepsy; Female; Fixation, Ocular; Humans | 2009 |
Binasal visual field defects are not specific to vigabatrin.
Topics: Adult; Anticonvulsants; Chi-Square Distribution; Electrooculography; Epilepsy; Female; Humans; Male; | 2009 |
Tuberous sclerosis with homonymous hemianopsia.
Topics: Anticonvulsants; Child; Epilepsy; Female; Hemianopsia; Humans; Magnetic Resonance Imaging; Tuberous | 2009 |
Vigabatrin (Sabril) for epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Infant; Vigabatrin | 2010 |
Vigabatrin: an antiepileptic drug with major benefits but significant adverse effects.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Infant; Spasms, Infantile; Vigabatrin; Vision Disorders; V | 2010 |
Can we change the course of epilepsy in tuberous sclerosis complex?
Topics: Epilepsy; Humans; Tuberous Sclerosis; Vigabatrin | 2010 |
Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; gamma-Amin | 2010 |
[Epileptic spasms without hypsarrhythmia. A new case report and review of the literature].
Topics: Anticonvulsants; Diagnosis, Differential; Electroencephalography; Epilepsy; Female; Humans; Infant; | 2010 |
Retinal nerve fiber layer thickness in vigabatrin-exposed patients.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Nerve Fibers; Reproducibility o | 2011 |
Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroretinography; Epilepsy; Female; Humans; | 2011 |
Epilepsy: Vigabatrin treatment and visual field loss.
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2011 |
[Compassionate use of vigabatrin for intractable epilepsy in Japan].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Compassionate Use Trials; Drug Utilizat | 2011 |
Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity.
Topics: Analysis of Variance; Animals; Anticonvulsants; Antidepressive Agents; Depression; Disease Models, A | 2011 |
Screening for vigabatrin (Sabril ®) retinal toxicity in children.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Child; Child, Preschool; Enzyme Inhibitors; Epileps | 2011 |
Registry initiated to characterize vision loss associated with vigabatrin therapy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Hu | 2011 |
Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Developmental Disabilitie | 2011 |
[Enriched-enrollment randomized-withdrawal trials].
Topics: Abatacept; Anticonvulsants; Antirheumatic Agents; Arthritis, Juvenile; Child; Epilepsy; Humans; Immu | 2012 |
Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Epilepsy; Female; Microinjections; Rats; Rat | 2012 |
Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Middle Aged; Nerve | 2012 |
[The course and treatment of epilepsy in children with tuberose sclerosis].
Topics: Anticonvulsants; Child; Diet, Ketogenic; Epilepsy; Humans; Tuberous Sclerosis; Vigabatrin | 2012 |
The legacy of vigabatrin in a regional epilepsy clinic.
Topics: Ambulatory Care Facilities; Anticonvulsants; Epilepsy; Female; Humans; Male; Retrospective Studies; | 2002 |
Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Recovery of Function; Vigabatri | 2002 |
Effects of vigabatrin on epileptiform abnormal discharges in hippocampal CA3 neurons of spontaneously epileptic rats (SER).
Topics: Action Potentials; Analysis of Variance; Animals; Anticonvulsants; Bicuculline; Epilepsy; Excitatory | 2002 |
Vigabatrin and visual field disorders.
Topics: Cohort Studies; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2002 |
Effect of vigabatrin on the pharmacokinetics of carbamazepine.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Interactions; Drug The | 2002 |
Vigabatrin, tiagabine, and visual fields.
Topics: Anticonvulsants; Epilepsy; Humans; Nipecotic Acids; Retina; Tiagabine; Time Factors; Vigabatrin; Vis | 2003 |
Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Recovery of F | 2003 |
Field specific visual evoked potentials for assessment of peripheral field defect in a paediatric population.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Evoked Potentials, Visual; Female; Humans; Male; | 2000 |
Retinal function abnormalities in patients treated with vigabatrin.
Topics: Adolescent; Adult; Anticonvulsants; Color Perception Tests; Dark Adaptation; Electroretinography; Ep | 2003 |
Successful pregnancy in a patient with hyperoxaluria and combined liver and renal transplant.
Topics: Adult; Epilepsy; Female; Humans; Hyperoxaluria; Infant, Newborn; Kidney Transplantation; Liver Trans | 2003 |
P2X2 and P2X4 receptor expression is regulated by a GABA(A) receptor-mediated mechanism in the gerbil hippocampus.
Topics: 3-Mercaptopropionic Acid; Animals; Disease Models, Animal; Enzyme Inhibitors; Epilepsy; GABA Agents; | 2003 |
Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.
Topics: Adolescent; Adult; Anticonvulsants; Biological Availability; Drug Combinations; Drug Interactions; E | 1993 |
Vigabatrin: longterm follow-up of electrophysiology and visual field examinations.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Electrooculography; Electroretinography; E | 2003 |
Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Middle Aged; Vigabatrin; | 2004 |
[Changes in visual field of a child treatment with vigabatrin for 2 years].
Topics: Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Humans; Male; Vigabatrin; Vision Dis | 2003 |
Biphasic action of vigabatrin on cortical epileptic after-discharges in rats.
Topics: Animals; Cerebral Cortex; Electroencephalography; Electroshock; Epilepsy; Male; Rats; Rats, Wistar; | 2004 |
Interaction between anticonvulsants and human placental carnitine transporter.
Topics: Acetates; Amines; Aminoisobutyric Acids; Anticonvulsants; Carnitine; Carrier Proteins; Culture Techn | 2004 |
Scotopic threshold response changes after vigabatrin therapy in a child without visual field defects: a new electroretinographic marker of early damage?
Topics: Adolescent; Anticonvulsants; Dark Adaptation; Electroretinography; Epilepsy; Humans; Male; Retinal D | 2004 |
The central piriform cortex: anatomical connections and anticonvulsant effect of GABA elevation in the kindling model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Female; gamma-Aminobutyric Acid; Injecti | 2004 |
Are vigabatrin-associated visual field constrictions asymptomatic?
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2004 |
Spectrum of epilepsy in tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; H | 2004 |
Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
Topics: Adult; Anticonvulsants; Child; Epilepsy; Female; Functional Laterality; Humans; Male; Neurologic Exa | 2005 |
Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; | 2005 |
Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Drug Interactions; Epilepsy; Female; Fructose; Hu | 2005 |
[Electrophysiological monitoring of epileptic patients treated with Vigabatrin].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Electrooculography; Electroretinography; Epilepsy; Female; | 2005 |
[The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Resistance; Drug Therapy, | 2005 |
Visual defects associated with vigabatrin: a study of epileptic argentine patients.
Topics: Adult; Anticonvulsants; Argentina; Carbamazepine; Electroretinography; Epilepsy; Female; Humans; Mal | 2005 |
Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
Topics: Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedu | 2006 |
Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Topics: Adult; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Nerv | 2006 |
A pharmacogenetic exploration of vigabatrin-induced visual field constriction.
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Cohort Studies; Epilepsy; False Positive React | 2006 |
Autistic regression associated with seizure onset in an infant with tuberous sclerosis.
Topics: Anticonvulsants; Autistic Disorder; Developmental Disabilities; Epilepsy; Humans; Infant; Male; Regr | 2006 |
Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Disabled Children; Epilepsy; Female; Humans; I | 2006 |
Vigabatrin and visual field defects in pediatric epilepsy patients.
Topics: Adult; Anticonvulsants; Child; Drug Monitoring; Drug Therapy, Combination; Epilepsy; Female; Humans; | 2006 |
D-bifunctional protein deficiency associated with drug resistant infantile spasms.
Topics: 17-Hydroxysteroid Dehydrogenases; Anticonvulsants; Disease Progression; DNA Mutational Analysis; Dru | 2007 |
Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interaction | 2007 |
Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency.
Topics: Adolescent; Brain; Brain Diseases, Metabolic; Dystonic Disorders; Epilepsy; Extremities; GABA Agents | 2007 |
Vigabatrin and epilepsy: lessons learned.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administrati | 2007 |
Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Humans; Infant; Prospective Studies; Spasms, Infa | 2007 |
Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
Topics: Adolescent; Adult; Aged; Algorithms; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Fe | 2008 |
Vigabatrin and epilepsy: further lessons in early childhood.
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Cross-Cultural Comparison; Dose-Response Rela | 2008 |
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
Topics: Adult; Aged; Anticonvulsants; Electroretinography; Epilepsy; Female; Humans; Male; Middle Aged; Reti | 2008 |
[Epileptic seizures in childhood: from seizure type to diagnosis].
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Diagnosis, Differential; Electroencephalography; Ep | 2008 |
New antiepileptic drugs in pediatric epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilep | 2008 |
Management of epilepsy in tuberous sclerosis complex.
Topics: Anticonvulsants; Child; Drug Resistance; Epilepsy; Gene Expression; Humans; Infant; Prognosis; Prote | 2008 |
Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Enzyme Inh | 2008 |
Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Topics: Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroretinography; Epilepsies, Part | 2008 |
Omega-aminoaciduria induced by gamma-vinyl GABA.
Topics: Adult; Alanine; Aminocaproates; Aminoisobutyric Acids; beta-Alanine; Child; Epilepsy; Female; gamma- | 1984 |
gamma-vinyl GABA, and GABA and beta-alanine transamination.
Topics: 4-Aminobutyrate Transaminase; Alanine; Aminocaproates; beta-Alanine; Epilepsy; gamma-Aminobutyric Ac | 1984 |
[Vigabatrin symposium within the congress "Epilepsy Europe", 3 September 1992, Glasgow].
Topics: Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Vigabatrin | 1992 |
The rational management of epilepsy through greater understanding of the disease. May 27-28, 1994, Budapest. Proceedings.
Topics: Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Vigabatrin | 1995 |
Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administrati | 1995 |
The role of newer anticonvulsants in the management of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Australia; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gam | 1995 |
Immunologic aspects of vigabatrin treatment in epileptic children.
Topics: Anticonvulsants; CD4-CD8 Ratio; Child; Child, Preschool; Cytotoxicity, Immunologic; Epilepsy; Female | 1995 |
Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain.
Topics: Adult; Anticonvulsants; Brain; Brain Chemistry; Epilepsy; Female; gamma-Aminobutyric Acid; Glutamic | 1995 |
Status epilepticus during vigabatrin treatment: a report of three cases.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Anticonvulsants; Brain; Electroencephalography; Epi | 1995 |
Sabril--a new antiepileptic agent.
Topics: Anticonvulsants; Biological Availability; Epilepsy; gamma-Aminobutyric Acid; Humans; Vigabatrin | 1994 |
Synergism with GABAergic drugs in refractory epilepsy.
Topics: 4-Aminobutyrate Transaminase; Adult; Drug Synergism; Epilepsy; Female; GABA Antagonists; gamma-Amino | 1994 |
Epilepsy treatment in The Netherlands. Comparison of matched groups of two medical centres.
Topics: Adolescent; Adult; Carbamazepine; Diazepam; Epilepsy; Ethosuximide; Female; gamma-Aminobutyric Acid; | 1994 |
[Vigabatrin--a new antiepileptic agent].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Ac | 1994 |
Vigabatrin use in 72 patients with drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilep | 1994 |
Profound suppression of plasma alanine aminotransferase activity in children taking vigabatrin.
Topics: Adolescent; Alanine Transaminase; Anticonvulsants; Child; Child, Preschool; Epilepsy; gamma-Aminobut | 1994 |
New antiepileptic drugs already registered.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Epi | 1994 |
Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies.
Topics: Adolescent; Adult; Amino Acids; Aminocaproates; Carbamazepine; Carnosine; Epilepsy; Female; gamma-Am | 1993 |
Novel antiepileptic drugs: nursing implications.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug | 1993 |
Vigabatrin: a three year clinical analysis.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Cerebral Cortex; Dose-Response Relationship, Dru | 1993 |
Complex partial status after starting vigabatrin.
Topics: Adult; Aged; Aminocaproates; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epi | 1993 |
Vigabatrin in uncontrolled seizures: Belgian clinical experience. The Belgian Vigabatrin Evaluation Group.
Topics: Adolescent; Adult; Anticonvulsants; Belgium; Child; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Effects of single and repeated administration of vigabatrin on the performance of non-epileptic rats in a delayed non-matching to position task.
Topics: Aminocaproates; Animals; Anticonvulsants; Conditioning, Operant; Epilepsy; Male; Memory, Short-Term; | 1993 |
Vigabatrin--interference with urinary amino acid analysis.
Topics: 4-Aminobutyrate Transaminase; Adult; Amino Acids; Aminocaproates; Anticonvulsants; Child; Child, Pre | 1993 |
Gas chromatographic assay of vigabatrin enantiomers in plasma.
Topics: Aminocaproates; Anticonvulsants; Chromatography, Gas; Epilepsy; Humans; Indicators and Reagents; Ref | 1993 |
[Campaign against epilepsy].
Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Felbamate; Humans; Lamotrigine; Phenylcarbamates | 1993 |
Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients. A 5-year follow-up study.
Topics: Adult; Aminocaproates; Anticonvulsants; Drug Resistance; Electroencephalography; Epilepsy; Female; F | 1993 |
Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Aminocaproates; Anticonvulsants; Chromatography, High P | 1993 |
Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo.
Topics: 4-Aminobutyrate Transaminase; Adult; Aminocaproates; Anticonvulsants; Brain; Epilepsy; Female; gamma | 1993 |
Costing of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Argentina; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Costs | 1996 |
Vigabatrin in childhood epilepsy: a 5-year follow-up study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Evoked Potentials, Auditory, Brain S | 1995 |
[Current role of novel antiepileptics in the treatment of epilepsies].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Resistance; Epil | 1996 |
[New medical treatment of epilepsy].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Costs; Epile | 1996 |
An audit of the new antiepileptic drugs in clinical neurological practice.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gabapentin; | 1996 |
Fatal hepatotoxicity in a child treated with vigabatrin.
Topics: Anticonvulsants; Child, Preschool; Epilepsy; Fatal Outcome; gamma-Aminobutyric Acid; Humans; Liver D | 1996 |
If comparisons can be odious, so can assumptions.
Topics: Acetates; Amines; Anticonvulsants; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Epilepsy; Gab | 1996 |
Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome.
Topics: Chronic Disease; Clinical Trials as Topic; Epilepsy; Follow-Up Studies; gamma-Aminobutyric Acid; Hum | 1996 |
Vigabatrin.
Topics: Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Vigabatrin | 1996 |
A survey comparing lamotrigine and vigabatrin in everyday clinical practice.
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Epile | 1996 |
Human brain GABA levels rise rapidly after initiation of vigabatrin therapy.
Topics: Administration, Oral; Anticonvulsants; Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Magnetic Re | 1996 |
[Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients].
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Ac | 1996 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.
Topics: Adult; Anticonvulsants; Chronic Disease; Epilepsy; gamma-Aminobutyric Acid; Humans; Male; Vigabatrin | 1997 |
Optimizing the indication of vigabatrin in children with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Contraindications; Drug | 1997 |
Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).
Topics: Adult; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Male; Seizures; Sleep Apnea Syndr | 1997 |
Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 1997 |
Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Preschool; Drug Interactions; D | 1997 |
Homocarnosine and the measurement of neuronal pH in patients with epilepsy.
Topics: Adult; Anticonvulsants; Brain Chemistry; Carnosine; Epilepsy; Female; gamma-Aminobutyric Acid; Human | 1997 |
[Carbamazepine and vigabatrin in epileptic pregnant woman and side effects in the newborn infant].
Topics: Alkaline Phosphatase; Anticonvulsants; Carbamazepine; Chlorine; Drug Therapy, Combination; Epilepsy; | 1997 |
Studies of drugs in epilepsy cited by author are not evidence based.
Topics: Anticonvulsants; Carbamazepine; Drug Combinations; Epilepsy; Evidence-Based Medicine; GABA Agents; g | 1998 |
A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, P | 1997 |
Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Animals; Anticonvulsants; Bicuculline; Cyclohexaneca | 1998 |
Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment?
Topics: Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Guanidines; Humans; Infant; Propionates; | 1998 |
Role of vigabatrin and lamotrigine in treatment of childhood epileptic syndromes.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 1998 |
The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Chi-Square Distribution; Cycl | 1998 |
Sudden death in two patients with epilepsy and the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Topics: Adolescent; Adult; Anticonvulsants; Autopsy; Carbamazepine; Death, Sudden; Epilepsy; gamma-Aminobuty | 1998 |
Adverse effects of vigabatrin in Angelman syndrome.
Topics: Adult; Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Comorbidity; Epilepsy; Female; g | 1998 |
High-performance liquid chromatographic analysis of vigabatrin enantiomers in human serum by precolumn derivatization with o-phthaldialdehyde-N-acetyl-L-cysteine and fluorescence detection.
Topics: Acetylcysteine; Adolescent; Adult; Anticonvulsants; Chromatography, High Pressure Liquid; Epilepsy; | 1998 |
The economic effects of introducing vigabatrin, a new antiepileptic medication.
Topics: Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Health Care Costs; Humans; Models, Economic; Que | 1995 |
GABA changes with vigabatrin in the developing human brain.
Topics: Adult; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Acid; H | 1999 |
Visual field constriction in children treated with vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Vigabatrin; V | 1999 |
The management of epilepsy in a hospital for people with a learning disability.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Uti | 1999 |
Long-term treatment with vigabatrin - 10 years of clinical experience.
Topics: Anticonvulsants; Chronic Disease; Cohort Studies; Epilepsy; Female; Follow-Up Studies; gamma-Aminobu | 1999 |
Crystal structure of GABA-aminotransferase, a target for antiepileptic drug therapy.
Topics: 4-Aminobutyrate Transaminase; Amino Acid Sequence; Animals; Anticonvulsants; Binding Sites; Computer | 1999 |
Time course of the GABAergic effects of vigabatrin: is the time course of brain GABA related to platelet GABA-transaminase inhibition?
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Blood Platelets; Brain; Brain Chemistry; Dos | 1999 |
The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Clinical Trials as Topic; Cyclo | 1999 |
[Recurrence of herpes simplex encephalitis].
Topics: Acyclovir; Anti-Anxiety Agents; Anti-Inflammatory Agents; Anticonvulsants; Antiviral Agents; Benzodi | 1999 |
Visual field defects associated with vigabatrin therapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain; Electrooculography; Electroretinography; Epilepsy; | 1999 |
Efficacy of lamotrigine and vigabatrin in drug-resistant epilepsies of childhood.
Topics: Adolescent; Anticonvulsants; Chi-Square Distribution; Child; Child, Preschool; Drug Resistance; Elec | 1999 |
Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Evaluation Studies as Topic; Male; Mice; | 1999 |
Characteristics of a unique visual field defect attributed to vigabatrin.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Male; Severity of Illne | 1999 |
Importance of specifying the type of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child; Contraindications; Diagnosis, Differential; Epilepsies, Parti | 1999 |
Vigabatrin: an effective antiepilepsy drug--balancing the risk of visual dysfunction.
Topics: Anticonvulsants; Epilepsy; Humans; Risk Factors; Vigabatrin; Vision Disorders | 1999 |
Refractory epilepsy: treatment with new antiepileptic drugs.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Resist | 2000 |
[Vigabatrin in childhood epilepsy--personal experience].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Male; Vigaba | 1999 |
[Lamotrigine versus vigabatrin as an add-on therapy in refractory epilepsy: prospective study].
Topics: Adolescent; Adult; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Electroencephalography; | 2000 |
[Clinical analysis of the effectiveness and safety of vigabatrin].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Femal | 2000 |
[Vigabatrin in the treatment of intractable focal epilepsy in children and adolescents. Two-year study].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Male; Prospective St | 2000 |
A controlled study of vigabatrin and visual abnormalities.
Topics: Adult; Aged; Anticonvulsants; Case-Control Studies; Color Vision Defects; Dose-Response Relationship | 2000 |
Simple high-performance liquid chromatographic method to monitor vigabatrin, and preliminary review of concentrations determined in epileptic patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Calibration; Child; Child, Preschool; Chromatography, High | 2000 |
GABA(A)-mediated toxicity of hippocampal neurons in vitro.
Topics: Animals; Anticonvulsants; Bicuculline; Cell Survival; Cells, Cultured; Epilepsy; Female; Fetus; GABA | 2000 |
Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
Topics: Anticonvulsants; Epilepsy; Humans; Prevalence; Vigabatrin; Vision Disorders; Visual Fields | 2000 |
Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory Group.
Topics: Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Humans; Vigabatrin; Visual Field Tes | 2000 |
Acute effects of gamma-vinyl-GABA on low-magnesium evoked epileptiform activity in vitro.
Topics: Animals; Anticonvulsants; Epilepsy; Evoked Potentials; Female; Magnesium; Male; Pyramidal Cells; Rat | 2000 |
Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables.
Topics: Adolescent; Adult; Anticonvulsants; Dominance, Cerebral; Dose-Response Relationship, Drug; Epilepsy; | 2000 |
Recovery of visual field constriction following discontinuation of vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Epilepsy; Humans; Male; Middle Aged; Recovery | 2000 |
Visual function loss from vigabatrin: effect of stopping the drug.
Topics: Adult; Aged; Color Perception; Electrooculography; Electroretinography; Epilepsy; Female; Humans; Ma | 2000 |
Visual impairment in children with epilepsy treated with vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Male; Retrospective | 2000 |
Vigabatrin reduces epileptiform activity in brain slices from pharmacoresistant epilepsy patients.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Drug Resistanc | 2000 |
Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss.
Topics: Adult; Anticonvulsants; Area Under Curve; Electrooculography; Electroretinography; Epilepsy; Female; | 2000 |
Vigabatrin-associated visual field defects in children.
Topics: Adolescent; Anticonvulsants; Child; Enzyme Inhibitors; Epilepsy; Female; Humans; Male; Retrospective | 2000 |
Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
Topics: Adult; Electrooculography; Electrophysiology; Electroretinography; Epilepsy; Evoked Potentials, Visu | 2000 |
Visual and auditory evoked potentials during long-term vigabatrin treatment in children and adolescents with epilepsy.
Topics: Adolescent; Child; Electroencephalography; Epilepsy; Evoked Potentials, Auditory; Evoked Potentials, | 2000 |
[Clinical utilization of new anti-epileptic agents].
Topics: Acetates; Amines; Anemia, Aplastic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2000 |
Visual field defects associated with vigabratin monotherapy in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Vigabatrin; Vision Disorders | 2000 |
The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 2001 |
[On article by Gekht AB, Avakian GN, Gusev EI "Modern standards of diagnosis and treatment of epilepsy in Europe"].
Topics: Anticonvulsants; Epilepsy; Europe; Humans; Lamotrigine; Triazines; Vigabatrin | 2000 |
Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom.
Topics: Acetates; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Amines; Anticonvulsants; | 2001 |
Visual field loss associated with vigabatrin: quantification and relation to dosage.
Topics: Adult; Ambulatory Care; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Sched | 2001 |
Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats.
Topics: Animals; Anticonvulsants; Brain; Electroencephalography; Epilepsy; gamma-Aminobutyric Acid; Hippocam | 2001 |
The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Femal | 2001 |
Effects of antiepileptic drugs on cognition.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Cyclohexanecarboxy | 2001 |
Visual field constriction on vigabatrin.
Topics: Adult; Anticonvulsants; Epilepsy; Europe; Humans; Infant; Spasm; Treatment Outcome; Tuberous Scleros | 2000 |
Topiramate: new indication. A bulkier assessment file.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Fructose; Humans; Treatment Outco | 1999 |
Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance.
Topics: Anticonvulsants; Brain; Cerebral Ventricles; Epilepsy; Humans; Infant; Male; Metabolism, Inborn Erro | 2001 |
Single systemic dose of vigabatrin induces early proconvulsant and later anticonvulsant effect in rats.
Topics: Action Potentials; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Dru | 2001 |
Adverse events in medical management--vigabatrin as a paradigm of forensic responsibility with novel therapy.
Topics: Anticonvulsants; Decision Making; Epilepsy; Ethics, Medical; Humans; Informed Consent; Vigabatrin; V | 2001 |
Ethical dilemmas of potential adverse events.
Topics: Anticonvulsants; Epilepsy; Ethics, Medical; GABA Agonists; Humans; Informed Consent; Liability, Lega | 2001 |
Vigabatrin associated retinal dysfunction in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Evoked Po | 2001 |
No reversion in vigabatrin-associated visual field defects.
Topics: Adult; Aged; Anticonvulsants; Cross-Sectional Studies; Drug Therapy, Combination; Epilepsy; Female; | 2001 |
Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy.
Topics: Age Factors; Brain; Brain Mapping; Carbon Radioisotopes; Child; Child, Preschool; Epilepsy; Female; | 2001 |
GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
Topics: Anticonvulsants; Brain; Epilepsy; gamma-Aminobutyric Acid; Genomic Library; Humans; Ornithine-Oxo-Ac | 2001 |
Reversed visual field constrictions in children after vigabatrin withdrawal--true retinal recovery or improved test performance only?
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Humans; Recovery of Function; Retinal Diseases; Vigaba | 2001 |
Pregnancy registries in epilepsy.
Topics: Abnormalities, Drug-Induced; Acetates; Amines; Anticonvulsants; Australia; Cross-Cultural Comparison | 2001 |
[Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2002 |
Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.
Topics: Adult; Age Factors; Anticonvulsants; Epilepsy; Female; Humans; Longitudinal Studies; Male; Middle Ag | 2002 |
The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroretinography | 2002 |
Visual field constriction and electrophysiological changes associated with vigabatrin.
Topics: Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electrooculography; Electroretinography; Ep | 2002 |
Vigabatrin and retinal changes.
Topics: Adolescent; Adult; Anticonvulsants; Control Groups; Electroretinography; Epilepsy; Female; Humans; M | 2002 |
Visual field and electrophysiological abnormalities due to vigabatrin.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Electrooculography; Elec | 2002 |
Electro-ophthalmological recovery after withdrawal from vigabatrin.
Topics: Anticonvulsants; Electrooculography; Electroretinography; Epilepsy; Humans; Recovery of Function; Re | 2002 |
Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Color Perception; Epilepsy; Humans; Middle Aged; Vigabatri | 2002 |
Visual field constriction in 91 Finnish children treated with vigabatrin.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Disease Susceptibility; Dose-Resp | 2002 |
What to do when the first anticonvulsant does not work.
Topics: Aminocaproates; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Lamotrigine; Phenytoin; Treatment | 1992 |
Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy.
Topics: Adult; Aminocaproates; Anticonvulsants; Cerebral Cortex; Epilepsy; Female; Humans; Male; Microscopy, | 1992 |
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Brain Stem; Cerebral Cortex; Electroencephalogra | 1992 |
Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain Edema; Dogs; Dose-Response Relationship, Drug; Drug | 1992 |
Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin).
Topics: Age Factors; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; | 1992 |
Reversible motor disturbances induced by vigabatrin.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Epilepsy; Female; Humans; Hyperkinesis; Infant; Laughte | 1991 |
Vigabatrin and psychosis.
Topics: 4-Aminobutyrate Transaminase; Adult; Aminocaproates; Anticonvulsants; Brain; Dose-Response Relations | 1991 |
The effect of subchronic administration of vigabatrin on learning and memory in nonepileptic rats.
Topics: Amino Acids; Aminocaproates; Animals; Anticonvulsants; Avoidance Learning; Brain Chemistry; Cerebell | 1991 |
Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy.
Topics: Adolescent; Adult; Aged; Aminocaproates; Animals; Anticonvulsants; Biopsy; Brain; Cerebellum; Child; | 1991 |
Vigabatrin treatment of epilepsy.
Topics: Aminocaproates; Anticonvulsants; Epilepsy; Humans; Vigabatrin | 1991 |
Use of antiepileptic drugs in childhood epilepsy.
Topics: Adult; Aminocaproates; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Child, Presch | 1991 |
Evaluation of vigabatrin in refractory epilepsy.
Topics: Aminocaproates; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy; | 1991 |
Vigabatrin and behaviour disturbances.
Topics: Aggression; Aminocaproates; Anticonvulsants; Epilepsy; Female; Humans; Male; Neurocognitive Disorder | 1990 |
Vigabatrin--a new anti-convulsant.
Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Humans; Vigabatrin | 1990 |
Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children.
Topics: Adolescent; Aging; Aminocaproates; Anticonvulsants; Child; Epilepsy; Humans; Infant; Stereoisomerism | 1990 |
The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.
Topics: Adult; Aminocaproates; Anticonvulsants; Carnosine; Cerebrospinal Fluid Proteins; Epilepsy; Female; g | 1989 |
[Medical treatment of epilepsy].
Topics: Aminocaproates; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Oxcarbazepine; Valproic Acid; Viga | 1989 |
GABA in epilepsy: the pharmacologic basis.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain; Epilepsy; gamma-Aminobutyric Acid; Substantia Nigra | 1989 |
Mechanisms of action of new antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants; | 1989 |
Vigabatrin: a new anti-epileptic.
Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Humans; Vigabatrin | 1989 |
Vigabatrin in the treatment of epilepsy in children.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infa | 1989 |
Vigabatrin in epilepsy in mentally retarded patients.
Topics: Adult; Aminocaproates; Anticonvulsants; Electroencephalography; Epilepsy; Female; Humans; Intellectu | 1989 |
Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticonvulsants; Epilepsy; Evoked Potentials, Somatosensory | 1989 |
gamma Vinyl GABA (vigabatrin) in epilepsy: the international experience. Proceedings of a symposium. Cincinnati, Ohio, April 16, 1988.
Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Humans; Vigabatrin | 1989 |
Specificity of vigabatrin for the GABAergic system in human epilepsy.
Topics: Adult; Aminocaproates; Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Male; Vig | 1989 |
Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticonvulsants; Epilepsy; Evoked Potentials, Somatosensory | 1989 |
Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy.
Topics: Adult; Aminocaproates; Anticonvulsants; Epilepsy; Female; Humans; Male; Time Factors; Vigabatrin | 1989 |
gamma Vinyl GABA: current role in the management of drug-resistant epilepsy.
Topics: Aminocaproates; Anticonvulsants; Drug Resistance; Epilepsy; Humans; Vigabatrin | 1989 |
Effect of vigabatrin (gamma-vinyl GABA) on amino acid levels in CSF of epileptic patients.
Topics: Adolescent; Adult; Amino Acids; Aminocaproates; Anticonvulsants; Brain; Dose-Response Relationship, | 1988 |
Somatostatin, beta-endorphin, and prolactin levels in human cerebrospinal fluid during the gamma-vinyl-GABA treatment of patients with complex partial epilepsy.
Topics: Adult; Aminocaproates; Anticonvulsants; beta-Endorphin; Endorphins; Epilepsy; Humans; Prolactin; Rad | 1987 |
Focus on vigabatrin. Proceedings of a satellite symposium. 17th Epilepsy International Congress. Jerusalem, Israel, 6-11th September, 1987.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Animals; Anticonvulsants; Epilepsy; Humans; Vigabatrin | 1988 |
CSF soluble proteins and vigabatrin.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebrospinal Fluid Proteins; Epil | 1988 |
Evoked potential monitoring of vigabatrin patients.
Topics: 4-Aminobutyrate Transaminase; Adult; Aminocaproates; Anticonvulsants; Epilepsy; Evoked Potentials; F | 1988 |
A profile of vigabatrin.
Topics: Aminocaproates; Anticonvulsants; Epilepsy; Female; Humans; Male; Vigabatrin | 1988 |
Levels of total gamma-aminobutyric acid (GABA), free GABA and homocarnosine in cerebrospinal fluid of epileptic patients before and during gamma-vinyl-GABA (vigabatrin) treatment.
Topics: Adolescent; Adult; Aminocaproates; Carnosine; Dipeptides; Dose-Response Relationship, Drug; Epilepsy | 1988 |
Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study.
Topics: Adolescent; Adult; Aminocaproates; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Huma | 1988 |
Vigabatrin: no microvacuoles in a human brain.
Topics: Adult; Aminocaproates; Anticonvulsants; Astrocytoma; Brain; Brain Neoplasms; Epilepsy; Female; Human | 1987 |
One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain; Epilepsy; Female; gamma-Aminobutyric Acid; Gerbilli | 1987 |
Long-term study of gamma-vinyl GABA in the treatment of epilepsy.
Topics: Adolescent; Adult; Aged; Aminocaproates; Animals; Anticonvulsants; Brain Diseases; Child; Child, Pre | 1985 |